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 The transient receptor potential mucolipin 1 (TRPML1) is a lysosomal ion channel 
permeable to cations, including Fe2+. Mutations in MCOLN1, the gene coding for TRPML1, cause 
the lysosomal storage disease (LSD) Mucolipidosis type IV (MLIV). Recent evidence from our 
lab suggests that the lysosome functions as a cytoprotective organelle that works to sequester 
cytotoxic material to prevent cellular damage to other organelles. However, the role of TRPML1 
in the cell is disputed and the mechanisms of cell deterioration in MLIV are unclear. The recent 
demonstration of Fe2+ buildup in MLIV cells raised the possibility that TRPML1 dissipates 
lysosomal Fe2+ and prevents its accumulation. In order to determine the function of TRPML1 and 
identify the molecular mechanisms leading to MLIV pathogenesis, I have analyzed the 
involvement of TRPML1 in the cytoprotective function of the lysosome. Since Fe2+ catalyzes the 
production of reactive oxygen species (ROS), I set out to test whether or not the loss of TRPML1 
promotes ROS production by Fe2+ trapped in lysosomes. My data shows that TRPML1-deficient 
retinal-pigmented epithelial (RPE1) cells develop elevated levels of oxidative stress that promote 
lipid peroxidation, activation of mitochondrial fission factors, mitochondrial fragmentation, 
mitochondrial depolarization, and decreased mitochondrial metabolism. These deleterious effects 
of TRPML1 deficiency were aggravated by Fe2+ exposure, but were reversed by incubation with 
the antioxidant α-tocopherol. As this data suggests, TRPML1 redistributes Fe2+ between the 
lysosomes and the cytoplasm. This work has led to a better understanding of TRPML1’s role in 
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cellular cytoprotection and in lysosomal transition metal homeostasis with regards to Fe2+. As the 
oxidative burden in TRPML1-deficient RPE1 cell has been recapitulated in MLIV patient 
fibroblasts and the MLIV mouse model, this data has also provided new developments into the 
molecular mechanisms of MLIV pathogenesis. Beyond suggesting a new model for MLIV 
pathogenesis and identifying novel therapeutic treatments for MLIV, this data shows that 
TRPML1’s role in the cell extends outside of lysosomes. 
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1.0  INTRODUCTION 
1.1 OVERVIEW 
Mucolipidosis Type IV (MLIV) is a lysosomal storage disease (LSD) associated with the loss of 
the lysosomal transient receptor potential mucolipin 1 (TRPML1) ion channel. The exact function 
of TRPML1 is currently unclear, but recent data suggests that it functions as a divalent ion channel 
promoting the release of Ca2+ and transition metals such as Fe2+ and Zn2+from the lysosomal 
lumen. Although it has been shown to conduct these molecules, the effects of divalent metal 
permeability through TRPML1 have not been studied. Transition metals, such as Fe2+, have been 
found to accumulate in patients with MLIV. In order to determine if TRPML1has a role outside of 
the lysosome, I am interested in determining if the buildup of transition metals in TRPML1-
deficient cells affects any organelle or cellular function outside of the lysosome. My research 
project is centrally focused on determining what happens in the cell when the lysosomal ion 
channel, TRPML1, is mutated or deficient. Specifically, I wanted to know if other organelles or 
cellular functions outside of the lysosome are affected by loss of TRPML1. TRPML1 is encoded 
by the MCOLN1 gene and mutations in this gene result in the rare lysosomal storage disorder 
(LSD), MLIV. This disease has a significant neurodegenerative profile and is associated with 
microglia activation, motor dysfunctions, and the accumulation of cytoplasmic storage bodies. As 
with many other neurodegenerative diseases, there are no cures for this disease. By determining if 
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the loss of TRPML1 damages organelles aside from the lysosome and identifying the specific 
mechanisms by which this damage occurs I will be able to identify new targets for therapeutics to 
alleviate MLIV pathogenesis, and hopefully other neurodegenerative disease. 
 This dissertation is divided into 5 sections: 1) background information, 2) methods and 
materials, 3) the identification that TRPML1 deficiency in RPE1 cells induces oxidative stress, 4) 
the identification that oxidative stress initiated by TRPML1 deficiency alters the expression of 
protein regulators of mitochondrial dynamics to induce changes in mitochondrial morphology and 
alter mitochondrial metabolic activity, 5) conclusions and future directions. The remainder of 
Chapter 1 will review general information about lysosomal function, regulation, and dysfunction 
associated with disease, clinical manifestations in MLIV, and the current state of knowledge with 
regards to TRPML1 function, ROS, and mitochondrial function.  
1.2 LYSOSOMES 
The lysosome is a membrane bound intracellular acidic organelle that was first described in the 
early 1950’s by Christian de Duve (1). While his discovery was serendipitous, he was awarded the 
Nobel Prize. Since the first discovery of lysosomes and the identification that they are degradative 
organelles containing over 60 hydrolytic enzymes and approximately 25 membrane proteins (1-
3), the concentric view has stayed very much the same. It wasn’t until the discovery of the 
transcription factor EB (TFEB), in 2009 that people began to appreciate lysosomes as advanced 
organelles that are crucial regulators of cellular homeostasis (2,4). With the recent discovery of 
TFEB, the master regulator of lysosomal biogenesis, autophagy, and lysosomal function, what is 
known about the role of the lysosome has changed drastically. It is now known that lysosomes 
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play a critical role in substrate degradation, absorption of endocytosed materials, secretion, plasma 
membrane repair, and they also participate in the recycling of cellular molecules and damaged 
organelles (3). In order for lysosomes to maintain their degradative capacity, lysosomal hydrolases 
need to be maintained at pH of 5. In order to maintain this acidic environment, lysosomes contain 
several ion channels and transporters that create the functional environment for proper cellular 
degradation. Specifically, the lysosomal H+-ATPase utilizes ATP to pump protons from the 
cytosol into the lysosomal lumen generating an electrochemical gradient to maintain lysosomal 
pH (2).  
Lysosomes are found in virtually all eukaryotic cells where they appear as dark dense 
bodies within the cytosol (2). They can range in shape, being spherical or tubular, but they typically 
form a perinuclear pattern within the cell (2). Lysosomes are typically less than 1 μm in diameter, 
but depending on cell type they can be several microns (2,3). Lysosomal size and number is very 
dynamic, as it changes in response to cellular conditions and perturbations (2). They are limited 
by a single 7-10 nm phospholipid bilayer, but also contain an intralysosomal membrane that is rich 
in phospholipid bis (monoacylglycero)-phosphate, which is the main site of membrane degradation 
(5,6). Lysosomal membranes proteins are highly glycosylated and therefore their membrane is 
high in carbohydrate content (2). As a means of protecting the membrane from the highly lytic 
enzymes within the lumen, glycosylation at the luminal domains form a glycocalyx (7). The 
lysosome contains high levels of cellular Ca2+ that is necessary for the maintenance of cellular 
trafficking, recycling, and vesicular fusion (8).  
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1.2.1 Lysosomal Function 
The most important function of the lysosome is the intracellular degradation of biological polymers 
including proteins, nucleic acids, lipid, and carbohydrates. The lysosome receives both 
intracellular cargo and extracellular cargo for degradation. As seen in Figure 1, extracellular 
molecules are ingested through endocytosis and passed from the early endosome to the late 
endosome and finally to the lysosome. As cargo is delivered to the lysosome, it is exposed to the 
plethora of lysosomal enzymes, which work to degrade cargo (9). To promote lysosomal 
degradation the intracellular environment of each vesicle gets proceedingly more acidic as vesicles 
travel through the endocytic pathway en route to the lysosome. The low pH of the lysosome is not 
only important for the function of acid hydrolases, but it also promotes membrane trafficking. 
Therefore, disruptions in lysosomal pH have been associated with alterations in endocytic 
trafficking of proteins and lipids (2). 
In addition to endocytosis, the lysosome also participates in exocytosis, which is the 
expelling of nutrients into the extracellular environment. Initial data suggested that only 
specialized secretory cells undergo exocytosis, but recent evidence has shown exocytosis to occur 
in several cell types (10). Exocytosis facilitates plasma membrane repair and allows for cell-to-
cell signaling (11). Exocytosis is a two-step process, where lysosomes relocate to the periphery of 
the cell and fuse with other lysosomes, which is then followed by fusion with the plasma 
membrane, an event that is dependent on the release of Ca2+ (10).  
Lastly, the lysosome is important for sequestration, degradation, and recycling of intra-
cellular molecules and organelles, which occurs via a process known as autophagy (11). During 
this process a double membrane forms around damaged proteins, cytoplasmic components, and 
damaged organelles, which results in the formation of the autophagosome (12). Next, the contents 
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of the autophagosome are transported toward the lysosome, which is facilitated by dynein and 
microtubules (13). Once at the lysosome, the autophagosome can fuse with the lysosome to form 
an “auto-lysosome” or can briefly interact to transfer its contents that are ready for degradation 
(2). If the two vesicles fuse the inner autophagosomal membrane enters the lysosomal lumen where 
it and its contents are degraded, while the outer membrane fuses with the lysosomal membrane 
(14). Autophagy is classified into three categories including: chaperone mediated autophagy, 
microautophagy, and macroautophagy (2). In order to regulate autophagy, the mammalian target 
of rapamycin (mTOR) is crucial, as it is responsible for sensing the energy status of the cell thus 
determining when cellular content needs to be recycled. Under normal cellular conditions, mTOR 
interacts with TFEB and is associated with the lysosomal membrane keeping TFEB in the 
cytoplasm. However, under conditions of starvation TFEB is released and translocates to the 
nucleus where it can regulate gene expression in order to meet the needs of the cell (15).  
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Figure 1 Endocytosis, Autophagy, and Exocytosis 
Lysosomes are involved in endocytosis, autophagy, and exocytosis. Endocytosis is important for 
the internalization of extracellular material, cargo travels through the early endosome (EE) to late 
endosome (LE) before arriving in the acidic lysosome for degradation. Autophagy is the 
sequestration, degradation, and recycling of dysfunctional intracellular organelles and 
macromolecules. Exocytosis is the Ca2+ regulated movement and secretion of intracellular material 
into the extracellular space. Exocytosis aids in plasma membrane repair during injury. Figure 
modified from Settembre et al (11). 
 6 
1.2.2 Lysosomal Regulation 
As previously mentioned, the lysosome is essential for maintaining cellular homeostasis by 
regulating cellular clearance and energy production in response to environmental cues. In addition 
to this task, the lysosome is also important for regulating several physiological processes including 
cholesterol homeostasis, cytoprotection, cell death, autophagy, and plasma membrane repair. In 
order for the lysosome to properly regulate these processes, the cell utilizes regulatory gene 
networks to rapidly respond to environmental cues. Regulatory gene networks are utilized 
throughout the cell to regulate cellular responses to stress, such as the unfolded protein response.  
Until recently, the network regulating lysosomal biogenesis, autophagy, and lysosomal 
degradation remained unknown. The Coordinated Lysosomal Expression and Regulation 
(CLEAR) network was the first regulatory gene network associated with the lysosome. Since its 
discovery, the CLEAR network has been shown to regulate several lysosomal functions including 
maintenance of lysosomal pH, cellular responses to starvation, lysosomal degradation, and 
lysosomal biogenesis just to name a few (4,16-18). In 2009, the Ballabio lab showed that in 
response to conditions of starvation or lysosomal dysfunction via cellular stress or damage, the 
master transcription factor EB (TFEB) is activated (4). TFEB is a basic helix-loop-helix leucine 
zipper transcription factor that upon activation enters the nucleus and binds to the CLEAR 
consensus sequence within the promoter of lysosomal genes (19). This results in the transcriptional 
regulation of lysosomal genes allowing for the cell to respond to both lysosomal stress by making 
more functional lysosomes and environmental needs, such as starvation, by inducing autophagy 
and lysosomal degradation (18-21). 
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1.2.3 Lysosomal Storage Disorders 
Given the complexity of the lysosome, the multitude of cellular activities that it performs, and the 
number of lysosomal proteins, it is not surprising that defects in any one of these lysosomal 
components can have deleterious effects on cellular homeostasis. Additionally, defects in any 
lysosomal hydrolase or membrane protein typically results in impaired lysosomal degradation and 
the accumulation of storage material, a hallmark of lysosomal storage disorders (14).  
Lysosomal storage disorders (LSDs) are a class of rare metabolic disorders caused by deficiencies 
in specific lysosomal hydrolases or lysosomal proteins involved in lysosomal biogenesis and 
catalysis. To date, more than 50 hereditary LSD have been described that result in the accumulation 
of undigested macromolecules in the endocytic pathway (22). While LSDs are generally rare, they 
do have an incidence rate of about 1:7,000 births (22). While most LSDs are fatal, children 
typically appear normal at birth but begin to display clinical symptoms at around 12 months of 
age. In 2/3 of the known LSD the central nervous system is affected. Additionally, other organs 
including bones, liver, eyes, and skeletal muscle have also been affected in LSDs. As groups of 
LSDs have similar substrate accumulation, they are typically classified based on substrate 
accumulations for example sphingolipidoses accumulate sphingolipids, oligosaccharidoses 
accumulate oligosaccharides, and mucopolysaccharidoses accumulate mucopolysaccharidessome 
(14). LSDs can have a mixture of substrates making their classification more challenging (14). 
Patients suffering from LSDs not only suffer from symptoms as a direct result of lysosomal 
dysfunction, but the lysosomal accumulations of undigested substrates can also result in secondary 
defects such as oxidative stress, improper Ca2+ handling, perturbed metabolic function, and 
impaired autophagy (23-25). Unfortunately, the presence of these secondary defects complicates 
model systems when it comes to research.  
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1.3 MUCOLIPIDOSIS TYPE IV AND TRPML1 
Mucolipidosis type IV (MLIV) is a neurodevelopmental and neurodegenerative disease caused by 
mutations in Mucolipin-1 (MCOLN1), which encodes the lysosomal transient receptor potential 
ion channel mucolipin 1 (TRPML1). While the underlying genetic cause of this disease has been 
identified, the molecular mechanisms leading to disease pathogenesis and neurodegeneration are 
not well defined. This is due in part to the poor understanding of the role of TRPML1 within 
lysosomes. Characterizing the loss of TRPML1 is important, as it is not known whether the cellular 
defects in MLIV are directly caused by the loss of TRPML1 or are an indirect result of the 
accumulation of lysosomal storage material over time. Several labs are working to understand the 
exact function of TRPML1 in membrane fusion, Ca2+ release, and lysosomal ion homeostasis. 
Identifying the exact role of TRPML1 within the lysosome will lead to important developments in 
the molecular pathogenesis of MLIV, as well as general cellular function. The following sections 
will focus on the characterization of MLIV with regards to clinical manifestations, cellular 
pathology, molecular genetics, and developments in the structural and functional characterization 
of TRPML1. Lastly, current treatments and therapeutic approaches for MLIV and other lysosomal 
storage disorders will be discussed.  
1.3.1 Mucolipidosis type IV 
Mucolipidosis type IV (MLIV) is a rare autosomal recessive lysosomal storage disorder caused by 
severe or partial loss-of-function mutations in the gene MCOLN1, which encodes the lysosomal 
ion channel transient receptor potential mucolipin 1(TRPML1) (26-28). MLIV is characterized by 
severe neurodevelopmental and degenerative abnormalities with progressive visual impairment 
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(29). It was first described in the early 1970’s when a patient presented with mild developmental 
delays, cytoplasmic inclusions in cultured cells, and retinal degeneration (30). Since the first 
diagnosis of MLIV in 1974 it has subsequently been determined to be a pan-ethnic disorder, with 
approximately 80% of all cases occurring in the Ashkenazi Jewish (AJ) population (26,31). Within 
this population, it has been estimated that the carrier frequency is 1 in 100, which gives an 
estimated disease incidence of 1 in 40,000 (32,33). MLIV is only one of several LSDs that 
commonly occur in the Ashkenazi Jewish population, as Gaucher disease, Tay-Sachs disease, and 
Niemann-Pick types A and B have also been diagnosed in this population (34).  
1.3.2 Clinical Manifestations in MLIV 
MLIV is an early onset LSD, with most patients diagnosed within the first year of life with 
ophthalmological impairments and significant delays in mental and motor development (32,35). 
As developmental delays are similar to cerebral palsy, MLIV patients are often misdiagnosed 
(36,37). Normal vision may occur initially, but is often followed by progressive vision impairment 
within the first decade due to corneal clouding, strabismus, pigmentary retinopathy, and outer 
retinal degeneration, which ultimately leads to optic atrophy (29,38,39). Visual impairments are 
likely impacted by the presence of granular material and concentric lamellar bodies within corneal 
epithelial, conjunctiva epithelial, and retinal ganglion cells, which is discussed in section 1.3.3 
(40). While patients may live several decades, the oldest to date being 45, patients typically reach 
the upper limits of motor and language development by 12-15 months of age but remain 
neurologically stable later in life (32,34,41). Patients often have trouble speaking and develop 
spasticity and hypotonia, which significantly reduces motor function and the ability to walk 
independently (42). In addition to severe motor deficits, MLIV patients also present with iron 
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deficiency anemia, constitutive achlorhydria, and elevated serum gastrin levels, the latter is 
typically used as a diagnostic tool for MLIV (35,42).  
Neurologically, MLIV patients suffer from white matter dysmyelination and 
disorganization, dysregulation of neuronal-oligodendroglia interactions, corpus callosum 
hypoplasia, Purkinje cell death, cerebellar atrophy, reduced maintenance of retinal and optic nerve 
cells, and decreased signal intensity in basal ganglia (37,43-45). As several of these characteristic 
neurological features can be identified by magnetic resonance imaging (MRI), MRI has become a 
useful diagnostic tool (37,46). Unlike other mucolipidoses, dysmorphic features and 
organomegaly are not typically reported in cases of MLIV (29,35). Recent work from the 
Slaugenhaupt lab using the MLIV mouse model has challenged this central view of 
neurodegeneration in MLIV, as mice were found to have activation of microglia and astrocytes 
and reduced myelination but no evidence of neuronal loss (41). This study changes our current 
understanding of MLIV, as it shifts the central idea from the role of the lysosome in neuronal cells 
to their role in glia cell function. This study presents new possibilities for therapeutic targets in 
MLIV and other LSDs and additionally provides new avenues for understanding the mechanisms 
of disease. 
1.3.3 Cellular Pathology in MLIV 
Presentation and severity of ophthalmological impairments, psychomotor retardation, and 
neurological damage can vary between MLIV patients, but the buildup of undigested substrates in 
cellular inclusion is one phenotype of the disorder present amongst all patients (32,34,35,47). 
Electron microscopy (EM) of patient cells show concentric multi lamellar bodies and granulated 
electron dense vacuoles, indicating the presence of heterogeneous soluble proteins and lipid 
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aggregates (Figure 2) (32,34,48,49). Pathologically, MLIV is distinguished from 
mucopolysaccharidoses as there is no excretion of mucopolysaccharide and it is distinct from other 
mucolipidoses as lysosomal hydrolases remain functional, the latter may explain the absence of 
organomegaly (29,50). As with other LSDs, the storage material in patients with MLIV was found 
to be autofluorescent (51). The distinct morphology and autofluorescent nature of storage material 
allows for skin biopsies, acid-Schiff staining, and immunofluorescence to be used as diagnostic 
tools (44,47,51).  
While accumulation of cellular material within the lysosome would typically indicate 
dysfunction of a lysosomal hydrolase, all hydrolases responsible for the catabolism of storage 
materials are present (52,53). This suggests that the gene associated with MLIV rather than acting 
as a hydrolase, likely plays a role in regulating endocytic trafficking and/or lysosomal function, 
inevitably affecting the function of lysosomal hydrolases.  
Biochemical analysis has shown abnormal accumulations of sphingolipids, including 
gangliosides, phospholipids, glycoproteins, and mucopolysaccharides within cells (54). Cellular 
inclusions are present in cells from every tissue analyzed in MLIV patients, but exact composition 
of inclusions differs depending on cell type (34). For example, neurons primarily accumulate 
gangliosides, while hepatocytes and other non-neuronal cells primarily accumulate phospholipids 
(55). Changes in storage material heterogeneity in different cell types are likely due to cell type 
specific lipid composition, responses to mutations in TRPML1, and/or different transcriptional 
profiles present in different cell types (56). In order to understand how the loss of TRPML1 results 
in cell type specific responses and how different cells respond to endocytic insults, it is crucial to 
identify the exact function of TRPML1 within the lysosome.  
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Figure 2 RPE1 cells deficient for TRPML1 accumulate electron dense cellular inclusions 
(A) Electron micrograph of control RPE1 cells. (B) Electron micrograph of TRPML1 deficient 
RPE1. Note the presence of lamellated bodies and electron dense inclusion in TRPML1 deficient 
cells that are absent in control RPE1 cells.  
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1.3.4 TRPML1 Molecular Genetics 
In 1999, the Gusella lab utilized a genome wide linkage analysis to map the MLIV gene to the 
short arm of chromosome 19p13.2-13.3 situated between base pair positions 7,587,496-7,598,895 
(50). One year later, in 2000, three labs simultaneously cloned the mucolipin-1 (MCOLN1, 
NG_015806.1, NM_020533.2) gene, which encoded a novel protein with high similarity to the 
transient receptor potential (TRP) family of ion channels (26-28). MCOLN1 is ubiquitously 
expressed in all tissues, contains 14 exons, and encodes the transient receptor potential mucolipin-
1 (TRPML1) ion channel, which is 580 amino acids in length and has a molecular weight of 65kDa 
(28). As of August 2014, 28 mutations in both AJ and non-AJ patients have been described, two 
of these mutations, known as the founder mutations, account for 95% of the MLIV alleles in 
patients from the AJ population (37,57). These founder mutations include a splice variant 
(g.5534A→G) and a partial gene deletion (g.511-6944del) (26,29,31,37,50). While some 
mutations within the MCOLN1 gene result in complete loss of channel function, other mutations 
occur that cause channel inactivity and/or mislocalization of TRPML1 within the cell (58,59). 
Mutations in which the channel is mislocalized or remains inactive are more likely to respond to 
small molecule therapeutic treatments than mutations that result in the absence of TRPML1 
(discussed in section 1.3.7).  
Since the identification of the MCOLN1 gene, no splice variants have been identified in 
humans, but the mouse gene, Trpml1, has two alternatively spliced isoforms (60,61). While no 
splice variants exist in humans, gene duplications of MCOLN1 have occurred over time in humans 
and mice as Mucolipin-2 (MCOLN2) and Mucolipin-3 (MCOLN3) are present in both genomes 
and encode TRPML2 and TRPML3 proteins, two additional members of the TRPML ion channel 
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family (54,62). In other model organisms, additional studies have identified only a single gene 
belonging to the TRPML family in C. elegans (cup-5) and Drosphila (trpml, CG8743) (25,60,63).  
1.3.5 TRPML1 Structural Characterization 
TRPML1 is a member of the mucolipin (TRPML) subfamily of the transient receptor potential 
(TRP) protein family, which also includes the other subfamilies: TRPC, TRPM, TRPV, TRPA, 
and TRPP (64). TRP channels are widely distributed in all tissues and act as cellular sensors in 
response to external or intracellular stimuli such as temperature, sound, light, mechanosensation, 
PIP2, Ca2+, cyclic nucleotides, pH, phosphorylation potential, and osmotic pressure (64,65). In 
response to such stimuli, TRP channels are activated and induce depolarization of cellular 
membranes via the direct or indirect influx of Ca2+ and Na+ (65). Due to the diverse role of TRP 
channels, mutations in several TRP genes have been associated with diseases of the intestinal, 
renal, respiratory, cardiovascular, and nervous systems (65). 
While the crystal structure of TRPML1 has not been solved, both bioinformatics and 
biochemical data from other TRP channels have provided valuable insight about the topology of 
TRPML1 (Figure 3) (62,66). TRPML1, like other TRP channels, is made of six transmembrane 
domains (S1-S6) with both amino-terminal (N-) and carboxyl-terminal (C-) tails located within 
the cytoplasm (28). TRPML1 contains a putative TRP channel pore-forming loop located between 
S5 and S6 (62). Two negatively charged aspartic acid residues located within this region are 
predicted to aid in the formation of the pore (67).  
Immunostaining and fractionation studies have shown that TRPML1 localization is distinct 
from most other TRP channels, as it is predominantly localized to late endosomes and lysosomal 
(LEL) membranes (68-70). TRPML2 and TRPML3, other TRPML subfamily members, are also 
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localized to the endocytic pathway (71,72). As they are all localized to the endocytic pathway, 
they have been found to homo- and hetero-multimerize (73,74). Targeting of TRPML1 to LELs 
relies on the presence of two di-leucine motifs, ETERL15L and EEHSL577L, located within the N- 
and C-termini, respectively (75). The C-terminal di-leucine motif regulates indirect trafficking of 
TRPML1 from the Trans-Golgi-Network (TGN) to the plasma membrane followed by endocytic 
trafficking to the lysosome via interactions with adaptor protein 2 (AP2), while direct trafficking 
of TRPML1 from the TGN to LEL relies on the interaction of the N-terminal di-leucine motif with 
clathrin adaptor proteins 1 and 3 (AP1 and AP3) (67,69,76). It has recently been shown that LEL 
membrane association of TRPML1 is promoted by the palmitoylation of cysteine residues 
(C565CC) located within the C-terminal tail (69). The C-terminal tail also contains two potential 
protein kinase A (PKA) phosphorylation sites (Ser557 and Ser559) that are important for regulation 
of channel activity (77). In addition to phosphorylation by PKA, it has recently been shown that 
channel activity is highly regulated via the selective binding of specific phosphoinositides at 
several positively charged amino acid residues within a polybasic domain at the N-terminus 
(66,78-81). To activate the channel, PI(3,5)P2 binds to Arg61 and Lys62, while PI(4,5)P2 binds 
Arg42, Arg43 , and Arg44 to inhibit channel activity (66,78-81). Similar to its TRP channel relative, 
polycystic kidney disease protein 2 (PKD-2), TRPML1 contains a large luminal loop between S1 
and S2 that may be important for channel regulation (82). Within this loop, TRPML1 contains four 
N-glycosylation sites in addition to a cleavage site (83-85). The cleavage site is important for the 
proteolytic cleavage of TRPML1 within the lysosome by cathepsin B and other proteases (83-85).  
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 Figure 3 Predicted human TRPML1 structure 
Cartoon model of human TRPML1 structural aspects. TRPML1 contains six putative 
transmembrane domains. Both the N- and C-terminal tails are localized in the cytosol. Two di-
leucine motifs (ETERL15L and EEHSL577L) are located at the N- and C- terminals, respectively, 
and are responsible for late endosome and lysosomal localization. Several N-terminal positively 
charged amino acid residues are predicted phosphoinositide interaction sites (R61 and K62 interact 
with PI(3,5)P2 and R42R43R44 interact with PI(4,5)P2). A proteolytic cleavage site and four N-
glycosylation sites are located in the large first luminal loop. TRPML1 is a nonselective ion 
channel and is permeable to Ca2+, Fe2+, Zn2+, Na+, and K+. The putative pore-forming loop is 
located between S5 and S6 contains two negatively charged amino acid residues that help form 
the pore. Model adapted from figure in Wang et al., 2014 (75). 
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1.3.6 TRPML1 Functional Characterization 
While it is known that TRPML1 functions along the endocytic pathway, the exact function of 
TRPML1 is still up for debate. Studies in MLIV derived patient cells have shown several 
lysosomal associated defects (discussed in section 1.3.6.1 and 1.3.6.2), but whether these defects 
are a) directly related to the function of TRPML1 or b) an indirect result of chronic lysosomal 
dysfunction is not known. It is likely that the answer to this question and others involving TRPML1 
will remain unanswered until the exact function of TRPML1 is identified. There are currently two 
working models of TRPML1 function that explain the primary defect in MLIV. The first model 
(described in section 1.3.6.1), the “traffic/biogenesis” model, supports the idea that TRPML1 
releases Ca2+ that drives lysosomal-endosomal fusion necessary for normal degradation of 
endocytic material (86). The second model (described in section 1.3.6.2), the “metabolic” model, 
supports the idea that TRPML1 directly regulates lysosomal ion homeostasis necessary for the 
activity of lysosomal enzymes (86).  
1.3.6.1 TRPML1 “Traffic” Model 
Initially, the main physiological function of TRPML1 was thought to be the release of Ca2+, which 
is necessary for the SNARE-mediated fusion of the late endosome and lysosome. This idea led to 
the development of the “traffic” model, which proposed that TRPML1 directly regulates 
membrane traffic and when TRPML1 is absent, endocytic material that would normally be targeted 
for lysosomal degradation accumulates. In support of TRPML1’s role as a Ca2+ channel, and in 
support of the trafficking model, several labs have shown that loss of TRPML1 results in delays 
of lipid (Lactosyl Ceramide) trafficking in MLIV cells and in C. elegans (52,63 ,67,77). The 
presence of constitutive achlorhydria and increased serum gastrin levels may also be explained by 
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the proposed role of TRPML1 in lysosomal Ca2+ efflux, as Ca2+ efflux is important for proper 
membrane fusion and endocytosis. Inhibition of this cellular event, via the loss of TRPML1, would 
likely affect normal hydrochloric acid production in gastric parietal cells by preventing parietal 
cell activation and vesicular trafficking to the membrane (35,42). Whether it is the direct loss of 
TRPML1 or the secondary accumulation of cellular inclusions causing constitutive achlorhydria 
remains to be elucidated. Along the same lines, mutations in TRPML1 resulting in the 
accumulation of undegraded material may be impairing vision in retinal epithelial cells from MLIV 
patients (54). This model still leaves some open-ended questions, as it does not answer whether 
the delay in trafficking is a direct result of TRPML1 loss or if the buildup of storage material 
presents delays in trafficking. 
1.3.6.2 TRPML1 “Metabolic” Model 
The “metabolic” model relies on the idea that LSDs that are of clear metabolic origin develop 
delays in membrane trafficking (87). These delays are similar to what has been reported in MLIV. 
Therefore the function of TRPML1 is mimicking what is observed in other metabolic disorders. 
The idea of this model relies on the fact that TRPML1 is important for maintaining proper 
lysosomal ion homeostasis. Therefore in the absence of TRPML1, regardless of the enzymes 
present, lysosomal ion homeostasis is improperly regulated and enzymes are dysfunctional 
allowing for the accumulation of storage material similar to other metabolic LSDs. Just as the 
“traffic” model does not answer all of the questions about the role of TRPML1, neither does the 
“metabolic” model. While the “metabolic” model does not answer how loss of TRPML1 directly 
affects lysosomal ion homeostasis, more of the recently published data is in agreement with this 
model. Recently it was shown that MLIV cells accumulate both Fe2+ and Zn2+, which suggest that 
TRPML1 also plays a role in transition metal homeostasis (79,88). In order to determine which 
 19 
model better depicts the functional role of TRPML1, more data describing the functional role of 
TRPML1 in the lysosome is needed.  
1.3.6.3 TRPML1 and Transition Metal Toxicity 
Transition metals, such as Fe2+, Zn2+, Cu2+, and Ni2+, are essential molecules in all living systems. 
As an essential nutrient, they are involved in several cellular processes including gene expression, 
neurotransmission, enzymatic reactions, oxygen transport, energy metabolism, DNA synthesis, 
and structural maintenance and stabilization of proteins (89-94). While transition metals are 
indispensible for several cellular processes, their concentrations within the cell needs to be tightly 
regulated as excess levels cause cellular toxicity and insufficient levels have deleterious effects on 
the cell. Because of this, transition metals are widely recognized as environmental hazards due to 
their toxic and carcinogenic effects (93,95).  
Iron is the most common transition metal on earth. As a transition metal, iron is an 
exceptional electron donor as it quickly changes between valances, primarily Fe2+ and Fe3+ (91). 
In most cellular conditions, iron exists in the ferric (Fe3+) state and must be reduced to the ferrous 
(Fe2+) state to become redox active (93). While most metabolically active Fe2+ exists in Fe2+ 
binding proteins like hemoglobin and cytochromes, when levels of Fe2+ overwhelm Fe2+ binding 
proteins, excess free Fe2+ becomes destructive, as it is redox active. Iron contained in the lysosome 
is often found in the redox active ferrous (Fe2+) state due to the acidic and reducing lysosomal 
environment (93). Additionally, as the lysosome is responsible for degrading metalloproteins, like 
transferrin and cytochromes, lysosomes generally contain higher quantities of free metals, 
specifically redox active metals, making them more susceptible to oxidative stress (93,96). Redox 
active Fe2+ in the lysosome is likely to interact with hydrogen peroxide diffusing into the lysosome, 
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which catalyzes Fenton reactions. Fenton reactions result in the production of ferryl (Fe3+), 
hydroxide ions, and ROS in the form of hydroxyl radicals (91). In the case of TRPML1-deficient 
cells, it is likely the production of these radicals within the lysosome that can have downstream 
consequences leading to peroxidation of storage material, which generates lipofuscin and 
ultimately lysosomal membrane damage (91).  
Even when Fe2+ is maintained at physiological concentrations, the presence of low levels 
of redox active Fe2+ in the lysosome over time can result in the accumulation of lipofuscin, as seen 
in post-mitotic cells (93,97,98). Accumulation of lipofuscin has been implicated in susceptibility 
to oxidative stress and decreased lysosomal degradative function (93,99). Impairment of lysosomal 
degradation ultimately suppresses autophagy and normal recycling of dysfunctional organelles, 
allowing damaged organelles, like mitochondria, to accumulate. This has been observed in both 
aging models and LSDs, like MLIV (24,25,49,100,101). Transition metal toxicity has been linked 
with LSDs and several other neurological diseases including Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease, Wilson’s disease, and Friedreich’s Ataxia (58,88,102-104). The 
increasing occurrence of transition metal accumulation in diseases of neurological origin 
emphasizes the importance of proper transition metal homeostasis within cells, as perturbations in 
this process are detrimental.  
  Cells have evolved several mechanisms to maintain transition metal homeostasis in order 
to avoid cellular toxicity. Plasma membrane transporters, such as Copper Transporter 1 (CTR1), 
Divalent Metal Transporter 1 (DMT1), and Zrt-Irt-like Protein 1 (ZIP1), which aid in the efficient 
transport of transition metals from the extracellular environment into the cytoplasm (91,102,105-
109). Once in the cytoplasm, cells employ chaperones and metal storage proteins, like 
metallothioneins, to tightly bind metals to reduce their toxic effects (92,110). Additionally, 
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endocytosis contributes to cellular transition metal levels, as several metal bound proteins, like 
transferrin, and free metals are endocytosed by cells (93,111). Upon degradation of metal bound 
proteins in the lysosome, free metals are released into the lumen. Once in the lumen, they remain 
there and become redox active or are transported to the cytoplasm via lysosomal metal transporters, 
such as DMT1 (91). Recent data from MLIV patient fibroblasts indicates that DMT1 may not be 
the only lysosomal metal transporter, as both Zn2+ and Fe2+ were found to accumulate in cells 
deficient of TRPML1 (58,88). Interestingly, MLIV patients are also known to accumulate 
lipofuscin, suggesting that the lysosomal Fe2+ is in a redox active state (25,58) While these findings 
suggest that oxidative stress induced by redox active Fe2+ may play a role in MLIV pathogenesis, 
whether or not the accumulation of metals within the lysosome has detrimental effects on other 
areas of the cell is not known. Work discussed in Chapter 3 examines the status of oxidative stress 
and cellular functions outside of the lysosome in TRPML1-deficient cells to determine the extent 
of cellular damage by accumulation of transition metals, specifically Fe2+ (23). These findings 
have opened new and exciting avenues towards identifying the exact cellular function of TRPML1. 
1.3.7 Treatments for MLIV and other LSDs 
The search for treatments for several lysosomal storage disorders is an ongoing process, while 
treatments and therapies for some LSDs have been successful, no specific treatment has been found 
for MLIV. The search for therapeutic strategies for all LSDs is a difficult process as the underlying 
molecular causes and disease pathogenesis for LSD are still being discovered. Recent attempts to 
correct cellular abnormalities associated with MLIV using drugs like Nigericin and Chloroquine 
(CQ) that lower lysosomal pH have resulted in little success (33). It is likely that therapeutic 
treatments will remain unsuccessful until the exact function of TRPML1 is elucidated. 
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More recently, the Grimm lab has utilized small molecules to restore channel function and 
endolysosomal trafficking defects and to reverse the accumulation of heavy metals in TRPML1 
mutants in which the channel is either mislocalized or remains inactive (38). The small molecule 
MK6-83 was surprisingly able to induce channel activity, rescue aberrant lactosyl ceramide 
trafficking, and ameliorate zinc accumulation in several mutant expressing cells (F408Δ and 
F465L mutants for example) but not TRPML1-/- fibroblasts (38). While not applicable to all MLIV 
patients, this study suggests possible success in pharmacological treatment of a select group of 
MLIV patients who retain inactive or mislocalized TRPML1 mutations (38). This study is the first 
of its kind to rescue channel function, trafficking defects, and transition metal homeostasis defects 
in MLIV patient cells.  
Another exciting pharmacological approach is the use 2-hydroxpropyl-β-cyclodextrin, to 
induce transcriptional activation of the CLEAR network and TFEB to enhance and restore cellular 
clearance (112). It has been shown that the activation of TFEB increases lysosomal biogenesis, 
autophagy, and lysosomal exocytosis via intracellular release of Ca2+ by TRPML1 and increasing 
the population of lysosomes ready to fuse with the plasma membrane (19,113). This increase in 
exocytosis results in the cellular clearance of stored material and may help to alleviate secondary 
defects caused by accumulation of stored material within the lysosome. While activation of TFEB 
has been shown to effectively clear stored material in several LSDs, including Pompe’s disease, 
Batten disease, Neuronal Ceroid Lipofusinosis, Multiple Sulfatase Deficiency, 
Mucopolysaccharideosis Type IIIA. However, it has not produced promising results in MLIV 
models, as TRPML1 seems to be necessary for TFEB activated clearance (112-114). Not only does 
activation of TFEB appear to be effective for several LSDs, it has also been used to promote 
clearance in other neurodegenerative diseases, including both Parkinson’s and Huntington’s 
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disease (115,116). While pharmacological activation of TFEB seems promising to treat 
neurodegenerative diseases, additional studies need to be performed in order to understand the 
long-term consequences of upregulating TFEB.  
Until recently, neuronal health was the central focus of disease pathogenesis in MLIV and 
therefore therapeutic developments focused primarily on relieving lysosomal abnormalities and 
dysfunction that results in decreased neuronal health and eventual neurodegeneration. This central 
paradigm which focused solely on neurodegeneration has shifted since the Slaugenhaupt lab 
recently showed that the MLIV mouse model revealed activation of glial cells and astrocytes in 
combination with reduced myelination that does not coincide with neuronal loss (41). This finding 
will allow for future therapeutic treatments to target neuroinflammation and glial cells via glial 
progenitor cell replacement therapy (41). 
While therapeutic strategies for MLIV patients are unavailable, the most doctors can do for 
patients is to make them comfortable and improve quality of life. Many MLIV patients undergo 
intensive physical therapy treatments in combination with vision, speech, and occupational 
therapies to improve motor function and help with everyday tasks. In addition to physical therapy, 
iron supplementation is often used to treat iron deficiency anemia, which occurs as a result of the 
constitutive achlorhydria and poor nutrient absorption (117). Since MLIV patients often suffer 
extreme eye discomfort in addition to corneal clouding and retinal degeneration, doctors often 
prescribe increased lubrications and therapeutic contact lenses to decrease pain. In severe cases of 
MLIV associated with optic atrophy, conjunctiva and corneal transplants have been performed to 
temporarily correct visual impairments (118).  
For several other LSDs, therapeutic strategies have progressed rapidly in the last decade as 
a direct result of identifying the molecular underpinnings for each disease. For diseases caused by 
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deficient lysosomal hydrolases several therapeutic options exist, including enzyme replacement 
therapy (ERT), chaperone treatment, gene therapy, hematopoietic stem cell transplants, bone 
marrow transplants, and substrate reduction therapy (SRT) (119-122). Enzyme replacement 
therapy is the most effective and widely used treatment for LSDs. Since it was first approved to 
treat Gaucher disease, ERT has successfully been used to treat Fabry disease, 
Mucopolysaccharidosis types I, II, IV, VI, and Pompe’s disease (22,119,123,124). While ERT is 
effective, its inability to cross the blood brain barrier limits its therapeutic potential (14,125). In 
addition to the treatments above, combination therapy has also proven successful. Combination 
therapy involves the use of specific treatments, like SRT or ERT, in conjunction with drugs that 
target secondary effects, like inflammation, in hopes of gaining synergistic effects and managing 
multiple aspects of the disease (125,126). While all of these strategies have proven effective at 
altering phenotypes, ameliorating disease symptoms, and improving patient survival, thus far no 
strategy provides a cure (22). Additionally, as few treatments are accessible to the central nervous 
system, many strategies are unable to address neurodegeneration associated with most LSDs (14). 
Identifying therapeutic strategies that address neuropathic symptoms and treat neurodegeneration 
will pave the way for the future of LSD therapeutics.  
1.4 REACTIVE OXYGEN SPECIES 
Oxygen is an important component of several biological molecules and it is essential for cellular 
respiration and the production of energy (127). Given the redox potential of oxygen and the fact 
that oxygen is essential in the production of cellular energy via the electron transport chain (ETC), 
it is not surprising that superoxide, a reactive oxygen species (ROS), is produced in the 
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mitochondria since oxygen can be partially reduced (127). In healthy cells, antioxidant systems 
are in place to keep levels of ROS in check, but when too many ROS are produced or antioxidants 
are reduced, oxidative stress can occur (128).  
Recently, oxidative stress has been linked to several neurological and neurodegenerative 
disorders, including several LSDs, Alzheimer’s disease, and Parkinson’s disease (95). The LSDs 
associated with elevated levels of ROS include Gaucher, Fabry, GM1 and GM2 (Sandhoff and 
Tay-Sachs) gangliosidoses, Niemann-Pick type C, Mucopolysaccharideosis Type I and IIIB, 
Neuronal Ceroid Lipofuscinosis types I, II, III, and VI (129-139). The central nervous system 
seems to be the perfect environment for oxidative damage, as oxygen requirements in the brain are 
extremely high and antioxidants systems are generally weaker (127,140). Several mechanisms are 
responsible for elevated levels of oxidative stress in the brain, by identifying these mechanisms 
and developing antioxidant therapeutics to alleviate oxidative damage, it is likely I can reduce 
pathogenic effects associated with several diseases. The following sections will highlight the 
physiologically relevant reactive oxygen species, their source, their normal cellular function, ROS 
mediated cellular damage and oxidative stress, regulation of antioxidant systems in response to 
oxidative stress, the role of oxidative stress in disease, and the means of measuring ROS within 
the cell.  
1.4.1 Types of ROS 
Free radicals and reactive molecules derived from molecular oxygen are termed reactive oxygen 
species (ROS) (95). ROS include superoxide (O2-), hydroxyl radical (OH), hydrogen peroxide 
(H2O2), and peroxyl radical (ROO). ROS can be generated via non-enzymatic methods through 
the transfer of electrons directly to oxygen via coenzymes like in the ETC, or via enzymatic 
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methods by cellular enzymes including NADPH Oxidases (NOX), Xanthine Oxidase (XO), and 
lipoxygenase (141). Generation of intracellular ROS have been associated with mitochondria, 
lysosomes, endoplasmic reticulum, peroxisomes, plasma membrane, and the cytoplasm (127). 
Superoxide is the most abundant ROS and considered the “primary” ROS as it reacts with 
other molecules to give rise to “secondary” ROS (95). While the most abundant cellular ROS 
product is superoxide generated within mitochondria via electron leak in the electron transport 
chain, it can also arise from irradiation of oxygen (95,142). Hydroxyl radicals are highly reactive 
and considered very dangerous for the cell as they can react directly with DNA, inducing DNA 
damage (95,143). Hydroxyl radicals are produced in lysosomes by Fenton reactions, when Fe2+ 
reacts with H2O2 molecules resulting in the production of Fe3+, OH, and OH- (95,127). The 
resulting hydroxyl radicals promote intralysosomal oxidation, which eventually damages the 
lysosomal membrane allowing hydrolytic enzymes to move into the cytosol, where they can 
activate apoptotic cascades (100). Hydrogen peroxide is produced in peroxisomes as a result of 
oxygen consumption (95). It is known that peroxisomes not only produce hydrogen peroxide but 
they also contain catalase, which functions to prevent toxic accumulation of hydrogen peroxide 
(95). In cells, hydrogen peroxide acts as a signal molecule to modify signaling proteins (127). 
Peroxyl radicals are the protonated from of superoxide and include hydroperoxyl (HOO), which 
has been shown to be associated with lipid peroxidation (95).  
1.4.2 ROS Function and Oxidative Stress 
Energy production is an essential cellular function, as such; living cells are continually in the 
presence of ROS. In order to prevent cellular damage from high levels of ROS, cells must maintain 
their redox state by balancing the rate of ROS production and their removal (127,128). Low levels 
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of ROS, prove to be beneficial for cells, as they are important for physiological processes, since 
they function as second messengers in signal transduction pathways to promote cell survival, 
proliferation and migration (127,144,145). High concentrations of ROS, however, have been 
shown to be very damaging for cells as they interact with biological molecules promoting DNA 
damage, lipid peroxidation, and oxidation of proteins, that ultimately induces oxidative stress 
(140). As a way of combating this process, cells have developed antioxidant mechanism to reduce 
cellular levels of ROS (95). The antioxidant systems that cells use to maintain ROS include 
enzymatic antioxidants, like super oxide dismutase, glutathione peroxidase, thioredoxin reductase 
and catalase, and non-enzymatic antioxidants, like ascorbic acid, α-tocopherol, glutathione, and 
flavonoids (127). While enzymatic antioxidants primarily function by converting ROS into a non-
reactive species, non-enzymatic antioxidants work by neutralizing ROS, preventing lipid 
peroxidation, becoming radicals themselves, or by terminating free radical chain reactions (127). 
With these systems in place, healthy cells are able to maintain low to moderate levels of ROS.  
When cells are challenged with elevated levels of ROS, whether endogenous or exogenous, 
in order to avoid detrimental effects, they must be able to rapidly alter their antioxidant capacity. 
To do so, cells have employed the transcription factor nuclear factor-erythroid 2-related factor 2 
(Nrf2), which is considered the master regulator of antioxidant and cytoprotective genes (146-
148). Under normal physiological conditions, Nrf2 is bound to its inhibitor Kelch-like ECH-
associated protein 1 (Keap1) and is localized to the cytoplasm where it is continuously degraded 
by the proteasome upon ubiquitination of Nrf2 (Figure 4) (146,147). The inhibitor contains 
cysteine residues that act as redox sensors to detect changes in cellular ROS levels (146). Upon 
initiation of oxidative stress, the cysteine residues within Keap1 are oxidized inducing a 
conformational change that releases Nrf2 and prevents farther ubiquitination of Nrf2 (146,147). 
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Newly synthesized Nrf2 is then translocated to the nucleus and forms a heterodimer with other 
transcription factors, like Jun and Maf. The heterodimer then binds to antioxidant response 
elements (ARE) in the promoter region of several genes to activate their transcription (146). Target 
genes of Nrf2 include but are not limited to Superoxide Dismutase 1 (SOD1), Glutathione S-
transferase alpha-1 (GSTA1), Metallothioneines (MTs), NAD(P)H: quinone oxioreductase 1 
(NQO1), and Heme oxygenase-1 (HMOX1). As NQO1 and HMOX1 expression was used as an 
indirect measurement of cellular ROS in Chapters 3 and 4, I will elaborate on their cellular function 
(149). 
Heme oxygenase-1 (HMOX1/HO-1) is a ubiquitous inducible cellular stress protein, which 
functions in oxidative catabolism of heme to produce biliverdin, which is converted into the 
antioxidant bilirubin. Upon interaction with additional ROS, bilirubin is converted back into 
biliverdin promoting the neutralization of ROS thereby reducing cellular oxidative stress. 
Recently, HMOX1 has been recognized for its role in cellular defense mechanisms, as it is known 
to confer antioxidant, anti-inflammatory, and anti-apoptotic effects (150).  
NAD(P)H: quinone oxioreductase 1 (NQO1) is a highly inducible antioxidant and 
cytoprotective enzyme (151). It is a flavoenzyme responsible for the reduction of quinones, which 
results in reduced potential for reactive oxygen intermediates to form via redox cycling (151). 
NQO1 has also been found to act as a scavenger for superoxide, a gatekeeper for the 20S 
proteasome, and promotes stabilization of microtubules (151). 
While antioxidants systems are very good at alleviating the cellular burden of ROS, 
sometimes they are unable to overcome the accumulation of ROS. When antioxidants systems can 
no longer maintain the balance between ROS production and removal, this induces oxidative 
stress, which can have deleterious effects on cells (127). There are two mechanisms that lead to 
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oxidative stress. The first involves the generation of too many ROS, which has been associated 
with aging, inflammation, and chronic diseases (95). The second mechanism stems from inhibition 
of cellular systems important for eliminating ROS, which has been associated with diseases like 
Parkinson’s disease and some LSDs, which exhibit reduced levels of glutathione (95,152,153). 
Oxidative stress in cells results in several detrimental phenotypes including lipid peroxidation, 
cross-linked proteins and protein dysfunction, DNA peroxidation and gene mutations, and 
ultimately cell death (127). 
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Figure 4 Nrf2 transcriptional regulation in response to cellular oxidative stress 
Under normal cellular conditions, Nrf2 is bound to its inhibitor Keap1 and is localized to the 
cytosol where it is continuously degraded. Keap1 contains cysteine residues that act as redox 
sensors to detect changes in cellular oxygen levels. Upon initiation of oxidative stress, the cysteine 
residues within Keap1 are oxidized inducing a conformational change that releases Nrf2. Nrf2 is 
then translocated to the nucleus and forms a heterodimer with transcription factors, like Jun. The 
heterodimer then binds to antioxidant response elements (ARE) in the promoter region of several 
genes, which activates transcription. Figure adapted from Bataille et al (146).  
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1.4.3 Measuring ROS 
A substantial challenge in ROS biology is the ability to measure ROS levels and to determine their 
cellular localization. While several labs are working on developing new probes to clearly identify 
specific types of ROS, the tools that are currently available limit the extent of ROS research. The 
following section will discuss the current techniques available for measuring ROS within the cell, 
the benefits of each technique, and their limitations.  
 The first technique that I will discuss is an indirect measurement of ROS, where the ROS 
burden is measured by examining gene expression of ROS responsive and antioxidant genes. This 
method relies on the idea that cells challenged by ROS must alter their antioxidant capacity in 
order to combat new levels of ROS. This process is initiated by the transcription factor Nrf2 as 
previously discussed. This method requires the isolation of RNA, synthesis of cDNA, and analysis 
of transcript levels via quantitative polymerase chain reaction (qPCR). While this technique is 
rather useful in determining if cells are undergoing oxidative stress, it does not provide any 
information about the level of ROS present nor the type of ROS being generated. In Chapters 3 
and 4, this technique was used to examine the abundance of both HMOX1 and NQO1 mRNA 
abundance, which reflects the presence of oxidative stress.  
The next technique to examine ROS is the use of a fluorescent ratiometric probe called 
BODIPY® 581/591 C11 undecanoic acid. This dye is useful for assessing the impact ROS have on 
the cell. When cells are challenged with increased levels of ROS that are not opposed by 
antioxidants, ROS are able to damage the cell by oxidizing lipids, proteins, and DNA. This 
technique is used to examine cellular levels of lipid peroxidation. This fatty acid probe works by 
reacting with radicals generated by cellular oxidative stress. Upon oxidation, the fluorophore shifts 
fluorescence from red to green, which is indicative of lipid peroxidation (154). This method is also 
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an indirect measurement of oxidative stress and does not provide any information about the level 
of ROS nor the type of ROS present. Additional techniques are also available to measure lipid 
peroxidation such as the measurement of malondialdehyde (MDA) and 4-hydroxy-trans-2-nonenal 
(HNE), which are produced as byproducts of lipid peroxidation (155).  
The next technique is used to measure several ROS through the use of the cell permeant 
dye 2’,7’-dichlorodihydrofluorescein diacetate (H2DCFDA). This dye is used to measure 
intracellular ROS including superoxide, hydroperoxy radical, singlet oxygen, hydroxyl radical, 
and various peroxides (156). While this technique is widely used and relatively simple to examine 
localization of several ROS within the cell, it lacks specificity and therefore cannot be used to 
specifically identify ROS. A major drawback of using this dye is that it is easily photo-oxidized 
and can result in further production of ROS (156). Dihydroethidium (DHE) is another redox 
sensitive fluorescent probe. DHE emits blue fluorescence until it is oxidized by superoxide when 
it shifts to red emissions. While DHE can be used to assess the presence of ROS, it cannot be used 
to determine localization, as it is known to intercalate with DNA generating a fluorescent signal 
within the nucleus (157). MitoSOX Red is a variant of DHE, which is targeted to mitochondria to 
detect mitochondrial superoxide species. While MitoSOX Red can be used to determine the 
presence of mitochondrial superoxide, it cannot be used to determine exact levels of mitochondrial 
superoxide species (158). Additionally, genetically encoded ROS probes have recently been 
developed (142). While these techniques encompass the most common methods to examine 
intracellular ROS, as more probes are developed it will become easier to determine spatial and 
temporal intracellular ROS production.  
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1.5 MITOCHONDRIA 
Mitochondria are dynamic organelles that produce most of the cell’s energy. While mitochondria 
are most notably known for their role in energy production via the electron transport chain (ETC) 
and oxidative phosphorylation, which will be discussed later, mitochondria are also an essential 
component of signaling pathways as they act to integrate cellular signals and respond by regulating 
energy supply, ROS signaling, cellular homeostasis, autophagy and intrinsic apoptotic pathways. 
In addition to acting as integrators of cellular signals, mitochondria also play a role in Ca2+ 
homeostasis, nutrient metabolism, and heme biosynthesis. In order to perform these functions, 
mitochondria form highly dynamic networks that are continuously remodeled by fission and fusion 
(159-161).  
1.5.1 Mitochondrial Function 
Mitochondria are considered the power plant of the cell, as they are essential sites of aerobic energy 
production in eukaryotic cells (162). Mitochondria maintain energy production through oxidative 
phosphorylation that couples the flow of electrons through the electron transport chain to generate 
a proton gradient across the inner mitochondrial membrane (IMM). Throughout this process, an 
electro-chemical gradient is generated by a series of subsequent steps using 5 protein complexes 
containing several redox centers. The protons generated from the electron transport chain then 
travel from the matrix space via a proton-motive force through ATP synthase resulting in the 
production of ATP (162). As highly efficient ATP producers, cytosolic localization of 
mitochondria is not random, but rather mitochondria are often found where high amounts of ATP 
are needed by the cell (163). While most of the electrons generated in the ETC are utilized to 
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produce ATP, it is possible for electrons to leak out and be transferred to oxygen, which results in 
the production of superoxide (164). Superoxide generated within mitochondria has the potential to 
generate additional ROS and reactive nitrogen species, which at low levels are used for cellular 
signaling but when improperly controlled can be damaging to mitochondria and ultimately the cell 
(164). To determine if mitochondria are meeting the energy demands of the cell, assays have been 
developed to assess cellular metabolic activity. One such assay is the Seahorse Extracellular Flux 
assay, which has the ability to measure mitochondrial metabolism in an isolated environment 
providing a comprehensive view of cellular metabolism in an extremely sensitive manner among 
the same cell population. This assay monitors several aspects of cellular metabolism including 
basal respiration, ATP production, proton leak, maximal respiration, spare respiratory capacity, 
and glycolytic function. An additional assay often used to examine mitochondrial function and 
mitochondrial health is the measurement of mitochondrial membrane potential using fluorescent 
dyes.  
In addition to ATP production, mitochondria are dynamic organelles that maintain cellular 
homeostasis through regulation of cellular maintenance, survival, Ca2+ signaling/storage, 
metabolite synthesis, and apoptosis (165-167). The dynamic nature of mitochondria is important 
for several of these functions, as mitochondria respond to these cues by changing morphology, 
connectivity, size, and distribution (168). Mitochondrial dynamics need to be stringently regulated 
and depend on the balance between fission and fusion machinery. As imbalances between fission 
and fusion have been shown to negatively impact the viability and physiology of cells (169,170). 
In addition to regulated fusion and fission, the biogenesis of functional mitochondria and the 
elimination of dysfunctional mitochondria must be a tightly regulated process in order to ensure 
that cells are always equipped with healthy ATP generating mitochondria (167,171). One 
 35 
mechanism of mitochondrial quality control and a cellular survival pathway used to monitor and 
regulate the elimination of dysfunctional mitochondria is known as mitophagy (172). It is essential 
to constantly monitor dysfunctional mitochondria, as a buildup of several damaged mitochondria 
within a cell can activate apoptosis (173).  
1.5.2 Mitochondrial Dynamics 
Maintenance of mitochondrial morphology is crucial for energy production and cellular 
homeostasis, therefore mitochondria must be able to rapidly adjust their morphology in response 
to the metabolic needs of the cell (165). In healthy cells, mitochondria are continuously cycling 
between fragmented and tubular networks throughout the lifetime of a cell (174). However, when 
cells are challenged with cellular stressors, such as oxidative stress, apoptosis, necrosis, and 
autophagy, this intricate balance between fusion and fission shifts toward fission and often results 
in fragmented unhealthy mitochondria (159,175). The proteins responsible for maintaining this 
delicate balance in mitochondrial morphology are separated into two groups, the fission proteins 
and the fusion proteins (Figure 5).  
Fission of mitochondria is important for cellular health, as it ensures that damaged 
mitochondria are targeted for autophagy and promotes generation of new organelles (176). 
Mitochondrial fission is mediated by the cytoplasmic dynamin-related protein 1 (DRP1) which 
interacts with the outer mitochondrial membrane (OMM) proteins including, Fission protein-1 
(FIS1), Mitochondrial Fission Factor (MFF), and Ganglioside induced differentiation associated 
protein 1 (GDAP1), the latter will be discussed in section 1.5.3 (168). DRP1 is a large GTPase that 
is translocated to mitochondria to promote fission (168). FIS1, MFF, and GDAP1 have all been 
proposed to recruit DRP1 to the OMM scission site, but their exact role in mitochondrial fission 
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remains unknown (177). At this site, DRP1 promotes fission by forming multimeric ring 
complexes, which constrict following GTP hydrolysis resulting in fission of mitochondria (166). 
Recent evidence suggests that FIS1 and MFF influence the number of DRP1 proteins found on the 
OMM (177). Mitochondrial translocation of DRP1 is highly regulated by post-translational 
modifications which include phosphorylation by Cdk1/cyclin B kinase at Ser616 promoting fission, 
phosphorylation by cAMP PKA at Ser637 inhibiting fission, dephosphorylation by calcineurin at 
Ser637 increasing fission, polyubiquitination by Parkin, and sumoylation by MAPL to stabilize 
DRP1 on the mitochondria, thus promoting fission (166).  
As elongation of mitochondria favors maximal ATP synthesis, cells that rely heavily on 
oxidative phosphorylation are constantly undergoing mitochondrial fusion (176). Mitochondrial 
fusion is regulated by the OMM dynamin-like GTPases Mitofusins 1/2 (MFN1/2) and the IMM 
GTPase Optic Atrophy 1 (OPA1). MFN1/2 are integrated into the OMM, of the two, MFN1 is 
required by OPA1 to promote mitochondrial fusion (166). Mitochondrial fusion occurs when 
MFN1/2 tethers the OMM together, facilitating the remodeling of membrane lipids by hydrolysis 
of cardiolipin by mitochondrial PLD. This results in the formation of phosphatidic acid, which 
facilitates fusion by altering membrane curvature (166). Mitochondrial fusion is dependent on GTP 
hydrolysis to provide energy (178). OPA1 functions to promote IMM fusion. Upon the availability 
of GTP, OPA1 oligomerizes promoting fusion of the IMM (166). Regulation of mitochondrial 
fusion occurs through proteasome degradation or proteolytic cleavage of fusion machinery (166). 
Mitochondrial fusion typically occurs as part of a stress response but fusion also offers a method 
to evenly maintain organelle populations (166,174,179).  
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Figure 5 Schematic representation of mitochondrial fusion and fission proteins 
(A) During mitochondrial fusion, MFN1/2 link two adjacent mitochondria via their coiled-coil 
domains promoting OMM fusion. IMM fusion is regulated by OPA1 and occurs upon the 
hydrolysis of GTP. (B) During mitochondrial fission, post-translational modification of cytosolic 
DRP1 initiates its recruitment to mitochondria. At the OMM, DRP1 directly interacts with MFF 
and FIS1, which leads to formation of multimeric ring complexes that promote fission upon the 
hydrolysis of GTP. GDAP1 is known to function in mitochondrial fission and is anchored in the 
OMM via a transmembrane domain at the C-terminus (180). Figure adapted from Mandemakers 
et al (181) 
A. 
B. 
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1.5.3 GDAP1 Function  
The GDAP1 gene maps to chromosome 8q21.1 and encodes the ganglioside induced 
differentiation associated protein 1 (GDAP1), which is expressed primarily in neurons (76,182-
184). The GDAP1 protein is involved in mitochondrial fission, as it has been shown to localize to 
the OMM, and more recently has been shown to affect Ca2+ homeostasis and possibly 
mitochondrial transport (65,183,185). Over expression of GDAP1 has been shown to induce 
mitochondrial fragmentation, without activating apoptosis in COS-7 cells (183,185). Mutations in 
GDAP1 are associated with both dominant and recessive forms of Charcot-Marie-Tooth (CMT) 
neuropathies (185). GDAP1 is characterized as a new member of the glutathione S-transferase 
(GST) family based on sequence similarity (182). Members of the GST family promote cellular 
detoxification by catalyzing reactions of the antioxidant glutathione to detoxify peroxide 
metabolites (186). Whether or not GDAP1 actually has GST activity is not known, but recent data 
indicates that GDAP1 expression was critical for protection against oxidative stress in response to 
low glutathione levels, as cells expressing mutant GDAP1 did not survive (187). This result 
indicates that GDAP1 may have a protective effect under oxidative stress conditions and suggests 
that CMT could be linked to oxidative stress. Interestingly, data in Chapter 4 also supports this 
hypothesis. Recent work with GDAP1L1, the cytosolic GDAP1 paralog expressed primarily in the 
central nervous system but also in neurons, suggests that GDAP1-family members act in a 
protective manner against stress caused by elevated levels of oxidized glutathione (185). 
Interestingly, overexpression of GDAP1 increased total cellular glutathione concentrations in a 
manner that elevated mitochondrial membrane potential, suggesting that GDAP1 promotes 
protection from oxidative stress (187). As little is known about the regulation of GDAP1 and its 
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exact cellular function, future work in this area will provide valuable insight into the protection 
that GDAP1 provides in instances of cellular and oxidative stress.  
1.5.4 Mitochondrial Damage and Dysfunction in Disease 
As mitochondria are responsible for producing most of the cells energy and maintenance of 
mitochondrial dynamics are important for energy production, it is not surprising that several 
neurological diseases are associated with mitochondrial dysfunction, as the brain is one of the most 
energy demanding organs in the body (188). Several neurological and neurodegenerative diseases 
are associated with mitochondrial dysfunction such as mitochondrial morphology defects, 
increased sensitivity to apoptosis, electron transport chain induced oxidative stress, and reduced 
metabolic function (188). Interestingly, several of these neurodegenerative diseases associated 
with mitochondrial dysfunction, are also associated with brain metal accumulations (188). While 
all of these diseases have similar physiology and disease phenotypes, it is still unclear if metals 
accumulation causes mitochondrial dysfunction, or if mitochondrial dysfunction causes metal 
accumulation. As my data in Chapter 3 and 4 suggests that MLIV is a member of this disease class, 
the impact of my findings can be applied in a much broader context outside of general LSDs. 
Additionally, recent evidence in several neurological and neurodegenerative diseases not typically 
associated with mitochondrial dysfunction have linked disease pathogenesis to alterations in 
mitochondrial morphology and metabolism. 
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2.0  MATERIALS AND EXPERIMENTAL METHODS 
2.1 CELL CULTURE AND BRAIN TISSUE 
Human retinal pigmented epithelial 1 (RPE1) cells immortalized with hTERT were cultured in 
Dulbecco modified Eagle medium (DMEM)/Ham F12 ((DMEM/F12), 1:1 mix) (HyClone, Logan, 
UT) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA) and 
grown at 37°C in 5% CO2. HeLa cells and WGO987 (Control) and WGO0909 (MLIV) patient 
fibroblasts were cultured in DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with 10% FBS 
and grown at 37°C in 5% CO2. Brain tissue isolated from two and six month old TRPML1 -/- 
knockout mice and wild-type (WT) littermate controls (n=4 for each condition), was obtained as 
a collaboration with Susan Slaugenhaupt’s lab at Harvard Medical School. 
2.2 TREATMENTS 
All Fe2+ treatments were performed in DMEM/F12 with 100 µM iron (II) chloride tetrahydrate 
(Sigma) for the indicated times. All Zn2+ treatments were performed in DMEM with 100 µM zinc 
chloride (Sigma) for the indicated times. All α-Tocopherol (α-Toc) treatments were performed in 
DMEM/F12 with 100 nM α-Toc (Sigma) for 24 hours prior to experiments. Mitotracker, mitosox, 
C11-BODIPY staining and imaging, and JC-1 fluorescence reading were performed in regular 
buffer which contained, in mM: 150 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, pH 7.4, and 1 
g/L glucose. All tert-Butyl hydroperoxide (TBHP) treatments were performed for 4 hours with 200 
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μM TBHP (Invitrogen, Carlsbad, CA). For analysis of Annexin V binding and Caspase 3 activity, 
cells were treated with 100 nM Staurosporine for 12 hours prior to analysis.  
2.3 siRNA MEDIATED KNOCKDOWNS 
For all KD’s, the following genes were targeted with the siRNA indicated in Table 1, MCOLN1, 
PPT1, GDAP1, DRP1/DNM1L, RAB5A, RAB7A, FIG4, VAC14, PIP5K3, TPC1, and ATP13A2 
(189,190). Non-targeting control siRNA#1 purchased from Sigma was used as a negative control. 
For knockdown of endogenous genes, RPE1 cells were plated in either 12 well plates (qPCR) or 
35 mm dishes (with or without glass coverslips for all other experiments) and grown to ~70% 
confluency. As described by manufacturer’s protocol, cells were transfected with either control or 
appropriate siRNA using Lipofectamine RNAiMAX (Invitrogen). Transfections were performed 
using 300 nM siRNA per 35 mm dish 72 hours prior to analysis. To confirm the efficiency of each 
knockdown, SYBR-green based qPCR was performed. In the case where appropriate antibodies 
were available, protein levels were also examined.  
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Table 1 siRNA gene targets and target sequence 
2.4 RNA ISOLATION AND cDNA SYNTHESIS 
Total cellular RNA was extracted from cultured RPE1 cells or patient fibroblasts grown in 12 well 
plates using TRIzol (Invitrogen) as per the manufacturer’s instructions. For isolation of RNA from 
mouse brain tissue, tissue was homogenized in Trizol as per the manufacturer’s instructions. For 
cDNA synthesis, 2 µg total RNA was annealed with 0.5 µg oligo (dT)18 primer (Thermo Scientific, 
Waltham, MA and IDT, Coralville, IA) followed by reverse transcription with MuLV Reverse 
Transcriptase (Applied Biosystems, Foster City, CA). 
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2.5 REAL TIME QUANTITATIVE PCR (qPCR) 
qPCR was performed using 1:1000 dilutions of cDNA, 2X SYBR green (Fermentas, Glen Burnie, 
MD), and 4 µM primer per 10 µl reaction. The following genes were amplified using the primers 
indicated in Table 2; RPL32, MCOLN1, HMOX1, PPT1, GDAP1, MFN1, NQO1, ActB, TPC1, 
RAB7A, RAB5A PIP5K3, VAC14, FIG4, DRP1/DNM1L and ATP13A2. All IDT primers were 
designed to span exons and negative RT controls were tested to ensure amplification of cDNA 
only. qPCR was performed using the Relative Quantification method on the 7300 Real Time 
System (Applied Biosystems). Reactions were run on the following parameters: 2 minutes at 50°C, 
10 minutes at 95°C, and 40 cycles at 95°C for 15 sec followed by 60°C for 1 minute. All biological 
assays were run in triplicate. Relative gene expression were calculated using the 2-ΔΔCt method, 
where Ct indicates cycle threshold (191). Data are presented as percent difference in expression 
upon normalization to the house keeping genes, RPL32 or ActB where indicated, and relative to 
control-KD cells, WGO987 (control) fibroblasts, or WT littermate controls.  
Table 2 qPCR primers 
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2.6 QUANTIFICATION OF LC3B-II/LC3B-I RATIO 
Autophagic flux was analyzed by measuring the ratio of LC3B-II and LC3B-I in RPE1 cells. As 
described in Wang et al., RPE1 cells were plated in 6 well plates and separately transfected with 
control or appropriate siRNA for 72 hours prior to collection (192). RPE1 cells were treated with 
20 μM Chloroquine for 12 hours prior to isolation as a positive control used to obtain the maximal 
LC3B ratio. As a negative control, RPE1 cells were pretreated with 2.5 mM 3-MA for 24 hours to 
prevent the initiation of autophagy, thus producing the minimal LC3B ratio. Prior to isolation, cells 
were washed one time with cold PBS and then scraped in 1 ml of cold PBS. The suspension was 
placed in a centrifuge tube and centrifuged at 2,000-x g to collect the cells. Cells were then 
resuspended in cold lysis buffer that contained: 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 2% 
Triton X-100 with 2 mM phenylmethanesulfonyl fluoride (PMSF) in 2-propanol. Cells were 
incubated on ice after resuspension and then centrifuged at 16,000-x g for 10 minutes at 4°C. The 
supernatant was collected and the protein concentration was measured using the Bradford (Bio-
Rad) protein assay. Samples were resuspended in 4X SDS, boiled for 5 minutes, and then 20 µg 
of protein were loaded on to a precast 12% Tris-Glycine gel, ran, and then transferred to PVDF 
membranes. The membranes were blocked with 10% (w/v) non-fat dry milk in TBS-T and then 
probed with polyclonal rabbit anti-LC3B antibody (Abcam, ab48394) diluted 1:1000 or 
monoclonal β-actin (Abcam, AC-15) diluted 1:5,000, washed, and probed with HRP conjugated 
goat-anti-rabbit secondary antibody (Amersham, Piscataway, NJ) diluted 1:5,000. 
Immunodetection was performed with the Luminata Forte HRP substrate (Millipore) and band 
densities were measured using ImageJ (Bethesda, MD) software. Levels of LC3B-II and LC3B-I 
were normalized to actin and the LC3B ratio was calculated by dividing LC3B-II by LC3B-I. Note 
that for analysis of LC3B-II, lower exposure times were used in quantification.  
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2.7 MEASUREMENT OF LIPID PEROXIDATION 
RPE1 cells were plated onto glass coverslips and transfected with control or TRPML1 959 siRNA 
72 hours prior to staining with 3 µM BODIPY 581/591 C11 undecanoic acid in regular buffer for 
30 minutes at 37°C in 5% CO2. Cells were washed with regular buffer prior to live cell imaging 
using a Leica TCS SPF confocal microscope. Probes were excited with an argon ion laser set at 
488 nm while emission was detected at 498-544 nm for peroxidated probe and 580-620 nm for 
nonoxidized probe. Image analysis was completed using ImageJ to calculate oxidation % = 
100%*Green/(Green + Red), where Green and Red are pixel values of images. 
2.8 MEASUREMENT OF MITOCHONDRIAL MEMBRANE POTENTIAL 
RPE1 cells were plated onto 35 mm dishes and separately transfected with control or appropriate 
siRNA for 72 hours prior to staining for 20 minutes at 37°C in 5% CO2 with the mitochondrial 
membrane potential sensitive dye, JC-1 (5 µg/ml in DMEM/F12 supplemented with 10% FBS). In 
the presence of mitochondrial membrane potential, JC-1 forms aggregates that fluoresce with an 
emission peak at 590 nm, while mitochondria that have lost their membrane potential favor the 
monomeric form of JC-1, which has an emissions peak at 530 nm (193,194). Cells were dissociated 
with 0.05% trypsin (Invitrogen) and washed once with room temperature regular buffer prior to 
measuring fluorescence. Fluorescence of JC-1 monomers and aggregates were measured using a 
fluorometer with the excitation/emission set at 485/530 nm and 535/590 nm, respectively. ΔΨm 
was inferred from the ratio of fluorescence at 590 nm (Red) and 530 nm (Green). Carbonyl cyanide 
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m-chlorophenylhydrazone (CCCP, Sigma, 10 µM), which collapses the ΔΨm, was used as a 
positive control.  
2.9 FLOW CYTOMETRY AND ANALYSIS 
The Vybrant™ Apoptosis Assay Kit #3 (Invitrogen, V-13242) was used for analysis of cell death 
by measuring green fluorescence in Annexin V positive cells via flow cytometry. Briefly, RPE1 
cells were grown in 6-well plates and transfected separately with control or TRPML1 959 siRNA 
24 hrs prior to treating with 100 µM Fe2+ for 24 hrs. To count the cells prior to flow cytometry, 
cells were washed in PBS (Lonza, Basel, Switzerland) and trypsinized in 0.05% trypsin 
(Invitrogen). To stain cells, 5 x 105 cells were resuspended in the Annexin Binding Buffer and 
loaded for 15 minutes with 2 µl of FITC Annexin V and 1 µl of propidium iodide (PI). Cells were 
sorted at the University of Pittsburgh Cancer Institute Cytometry Facility on the BD Accuri™ C6 
(Becton Dickinson, Franklin Lakes, New Jersey). To analyze the data the BD Accuri C6 software, 
side scatter, and forward scatter were used to gate events to exclude debris but include both healthy 
and apoptotic cells. Annexin V binds to cells that are undergoing apoptosis and express 
phosphatidylserine on the outer layer of the cell membrane, while PI enters cells with a 
compromised cell membrane and binds to cellular DNA (195). The staining of cells with these 
dyes allows for the separation of live cells (unstained), apoptotic cells (FITC Annexin stained, and 
necrotic cells (PI stained cells).  
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2.10 CASPASE 3 ACTIVITY ASSAY 
For analysis of Caspase 3 activity, RPE1 cells were plated in 6 well plates and separately 
transfected with control or TRPML1 959- siRNA for 72 hours prior to assay, some samples were 
treated with 100 µM Fe2+ for 48 hours prior to analysis. As a positive control, cells were treated 
with 100 nM Staurosporine for 12 hours prior to analysis. Cells were prepared and measured using 
the EnzChek Caspase 3 Assay Kit #1 (Invitrogen, E13183) following the manufacturer’s 
instructions. AMC substrate fluorescence was measured using a fluorometer at an excitation 
wavelength of 342 nm and an emission wavelength of 441 nm. Data are normalized to control and 
presented percent of control.  
2.11 MITOCHONDRIAL MORPHOLOGY ANALYSIS 
RPE1 cells grown on glass coverslips and transfected separately with control or TRPML1 siRNA 
were stained with 100 nM Mitotracker Green® FM (Invitrogen, Carlsbad, CA) in regular buffer 
at 37°C in 5% CO2 for 25 minutes followed by live cell imaging using a Leica TCS SPF confocal 
microscope. For data analysis, since each image contained complete cells and parts of cells, raw 
images were segmented using ImageJ, with each segment containing one complete cell (Figure 
14A). Each segment was then binarized using the thresholding function of ImageJ (Figure 14B). 
Threshold settings ranged between 55 and 255, to preserve the mitochondrial network 
characteristic of each specific cell. Mitochondrial morphological characteristics, including AR and 
FF, were calculated by obtaining the major and minor axes of the ellipse equivalent to the 
mitochondria, area, perimeter, and number of mitochondria using the analyze particle function in 
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ImageJ. All mitochondrial morphological analysis was completed using three biological replicates 
on three separate days.  
2.12 ROS LOCALIZATION 
To determine the localization of ROS species in TRPML1-deficient RPE1 cells, RPE1 cells on 
glass coverslips were transfected separately with control or TRPML1 siRNA 72 hours prior to 
imaging. Some samples were treated with 100 µM Fe2+ for 24 hours prior to imaging. Using the 
Image-IT® LIVE Green ROS Detection Kit for microscopy (Invitrogen, I36007) cells were loaded 
with 25 µM carboxy-H2DCFDA according to the manufacturer’s protocol. Cells were also loaded 
with Lysotracker® Red DND-99 using a 1:10,000 dilution in regular buffer then live cell imaging 
was performed using a Leica TCS SPF confocal microscope. Images were analyzed using ImageJ 
software.  
2.13 SUPEROXIDE QUANTIFICATION WITH MITOSOX™ RED 
Cells were plated on MatTek (Ashland, MA) dishes and transfected with siRNA to induce 
TRPML1 KD. Cells were exposed to Fe2+, α-Toc, or TBHP for indicated times prior to loading 
with superoxide probe MitoSOX™ Red (5µM, Invitrogen) for 15 minutes at 37°C in conjunction 
with Mitotracker Green® FM (1.5 µM, Invitrogen). MitoSOX™ Red and Mitotracker Green® FM 
were then imaged by mounting coverslip bottom dishes on a Nikon TiE inverted fluorescent 
microscope (Nikon, Melville NY) with a X60, 1.4NA optic equipped with a temperature-
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controlled chamber (Tokai Hit, Japan). Mitotracker Green® FM and MitoSOX™ Red dyes were 
excited using 488 and 513 nm and detected using appropriate filters for GFP and TRITC, 
respectively. For Mitotracker Green® FM, images were collected with the following settings: 
Light source 10%, 14 Bit: No binning, exposure: 40ms. For MitoSOX™ Red, images were 
collected with the following settings: Light source 20%, 14 Bit: Binning 2 x 2,exposure: 100 ms. 
Images were analyzed in NIS-Elements by adjusting the binary threshold to include appropriate 
mitochondrial localized TRITC signal, indicating actual MitoSOX™ Red signal. The threshold 
was set at low: 245 and high: 16383, smoothed 1X, cleaned 1X, and converted to a binary image. 
Measurements were obtained using the automated measurement tab; counts for mean TRITC 
intensity were exported to excel for statistical analysis. For each experiment at least 10 stage 
positions were measured. Experiment was repeated three times for most samples: n=3 for control 
untreated, control + α-Toc, TRPML1-959 untreated, TRPML1-959 + α-Toc; n=2 for control + Fe2+ 
and TRPML1-959 + Fe2+; n=1 for control TBHP. Quantification for TRPML1-959 +TBHP not 
included. 
2.14 SEAHORSE ASSAY FOR CELLULAR METABOLIC ACTIVITY 
To assess cellular metabolic activity with regards to basal oxygen consumption, glycolysis, ATP 
turnover, and mitochondrial respiration the Seahorse XF24 Extracellular Flux Analyzer was used 
(Seahorse Bioscience, North Billerica, MA). RPE-1 cells were transfected with control or 
TRPML1-959 siRNA 48 hours prior to plating cells (100,000 cells/well) in 24 well Seahorse cell 
culture microplate 24 hours prior to experiment. Cells were treated with either 100 µM Fe2+ for 48 
hours or 100 µM Zn2+ for 24 hours prior to experiment. One day prior to experiment, the sensor 
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cartridge was hydrated with calibration buffer. Prior to the start of the experiment, each well was 
washed with unbuffered DMEM, replaced with a final volume of 700 µL DMEM, and incubated 
at 37°C for 60 minutes. Upon cartridge calibration, basal extracellular acidification rates (ECAR) 
and cellular oxygen consumption rates (OCR) were measured followed by subsequent 
measurements upon the addition of 1 µM oligomycin, 300 nM CCCP, and 1 µM antimycin A (196-
198). For each compound in addition to basal measurements, three readings were recorded. For 
each experimental condition four replicates were averaged, normalized to total protein levels 
(measurement of cell number) per well, and compared using a one-tailed, unpaired t-test. 
Normalization of data at the cellular level with total protein provides information about the 
bioenergetic differences between cell populations (199).  
2.15 STATISTICAL ANALYSIS 
 Data are summarized as mean ± standard error of the mean (S.E.M.) of three independent 
experiments, unless explicitly stated. The statistical significance was assessed using a one-tailed, 
unpaired t-test with p≤0.05 considered significant. * indicates p ≤0.05, while ** indicates p≤0.01.  
 51 
3.0  LOSS OF TRPML1 PROMOTES PRODUCTION OF REACTIVE OXYGEN 
SPECIES 
The work discussed in this chapter was originally published in the Biochemical Journal and has 
been modified and reprinted with permission from © the Biochemical Society. The citation for the 
original publication is: 
Jessica Coblentz, Claudette St. Croix, and Kirill Kiselyov, “Loss of TRPML1 promotes production 
of reactive oxygen species: is oxidative damage a factor in Mucolipidosis type IV?” Biochemical 
Journal. 2014; 457: 361-368 © the Biochemical Society (23).  
TRPML1 is a lysosomal ion channel permeable to cations, including Fe2+. Mutations in 
MCOLN1, the gene coding for TRPML1, cause the lysosomal storage disease (LSD) 
Mucolipidosis type IV (MLIV). The role of TRPML1 in the cell is disputed and the mechanisms 
of cell deterioration in MLIV are unclear. The recent demonstration of Fe2+ buildup in MLIV cells 
raised the possibility that TRPML1 dissipates lysosomal Fe2+ and prevents its accumulation. Since 
Fe2+ catalyzes the production of reactive oxygen species (ROS), I set out to test whether or not the 
loss of TRPML1 promotes ROS production by Fe2+ trapped in lysosomes. My data shows that 
retinal-pigmented epithelial (RPE1) cells develop a punctate mitochondrial phenotype within 48 
hours of siRNA-induced TRPML1 knockdown (KD). This mitochondrial fragmentation was 
aggravated by Fe2+ exposure, but was reversed by incubation with the ROS antioxidant α-
tocopherol (α-Toc). The exposure of TRPML1-KD cells to Fe2+ led to: loss of mitochondrial 
membrane potential (ΔΨm), ROS buildup, lipid peroxidation and increased transcription of genes 
responsive to cytotoxic oxidative stress in TRPML1-KD cells. This data suggests that TRPML1 
redistributes Fe2+ between the lysosomes and the cytoplasm. Fe2+ buildup caused by TRPML1 loss 
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potentiates ROS production and leads to mitochondrial deterioration. Beyond suggesting a new 
model for MLIV pathogenesis, this data shows that TRPML1’s role in the cell extends outside 
lysosomes. 
3.1 INTRODUCTION 
TRPML1 is a member of the mucolipin family of transient receptor potential (TRP) ion channels 
(62,86). TRPML1 is encoded by the MCOLN1 gene, mutations in this gene result in the rare 
lysosomal storage disease MLIV (26-28). The disease has a significant neurodegenerative profile 
and is associated with motor dysfunction and the accumulation of cytoplasmic storage bodies 
(32,34). How the loss of TRPML1 causes severe neurodegeneration is currently unclear, but 
delineating the role of TRPML1 within the cell may provide insight into the pathogenesis of MLIV. 
TRPML1 is localized to lysosomes due to the presence of two lysosomal localization signals in its 
N- and C-termini (69,84). These signals are not evident in its relatives TRPML2 and TRPML3, as 
their localization appears to be wider (68,200,201). In addition to localization signals, TRPML1 is 
potentiated by a low lysosomal range of pH and its regulation by lysosomal phosphatidylinositol 
3,5-bisphosphate further limits its physiological context to the lysosome (58,80,202).  
TRPML1 conducts monovalent as well as divalent cations such as Fe2+, Zn2+, and Ca2+ 
(58,202). Its Ca2+ permeability has attracted the most interest, primarily in the context of its 
possible role in endocytic membrane fusion (67,203,204). A variant of this has also been discussed 
with regards to TRPML1’s role in lysosomal secretion (113,205). TRPML1’s role in membrane 
fusion has been discussed before (85,86,190,206).  
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Although TRPML1 was shown to conduct Fe2+ and TRPML1-deficient cells have been 
shown to accumulate Fe2+, its role in Fe2+ homeostasis have not been actively pursued (58). The 
pathways of Fe2+ entry into cells include endocytosis of protein-bound Fe2+, followed by its 
liberation and absorption in the late endocytic pathway. It may also enter lysosomes via autophagy 
of Fe2+-containing organelles and Fe2+-bound proteins. Fe2+ catalyzes production of ROS due to 
Fenton-like reactions, and ROS are damaging to several key aspects of cellular function, including 
DNA and mitochondrial damage and the buildup of lipofuscin (99). Therefore, I sought to answer 
whether or not TRPML1 loss has an effect on mitochondria and whether ROS mediate such an 
effect.  
Mitochondria are dynamic organelles that produce most of the cell’s energy and are 
essential components of signaling pathways that maintain cellular homeostasis and regulation of 
cellular responses to stresses. In order to maintain these functions, mitochondria form highly 
dynamic networks that are continuously remodeled by fission and fusion (159,160). When 
mitochondria become damaged, whether it is due to altered ΔΨm, loss of mtDNA, or ROS buildup, 
they need to be degraded in order to prevent the activation of downstream apoptotic cascades and 
cell death (170,207-209). The loss of mitochondrial membrane integrity is associated with 
collapsing ΔΨm, which can be ascertained using voltage-sensitive dyes targeted to mitochondria, 
such as JC-1 (193,194). Several means of mitochondrial damage have been identified including 
ROS, which have been implicated in mitochondrial permeabilization in a variety of systems. 
Damage like this to mitochondrial membranes takes place during stroke and ischemia, under which 
conditions of oxygen deprivation leads to ROS production and oxidation of mitochondrial lipids 
(170,210-214). Other causes of mitochondrial damage include overload with Ca2+ during 
excitotoxicity (215).  
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Mitochondrial shape is another readout of their status. Under resting conditions, the size 
(length) of mitochondria is dictated by the balance between mitochondrial fusion and fission events 
(159,160). The shape of mitochondrial networks can be altered by multiple cellular perturbations, 
including apoptosis, necrosis, and autophagy (159). In order to focus directly on the effects that 
the loss of TRPML1 has on mitochondria, I utilized a range of experimental conditions that do not 
induce marked increases in apoptosis, as apoptosis is often associated with fragmentation of 
mitochondria. 
Here I aimed to answer whether or not TRPML1 has a role beyond lysosomes and whether 
its functional status directly affects other organelles. I chose to utilize the expression of oxidative 
stress induced genes, ROS levels, lipid peroxidation, ΔΨm, and mitochondrial morphology as 
readouts of TRPML1’s impact on the cell beyond lysosomes. My data suggests that TRPML1 loss 
facilitates ROS production, in a manner that is aggravated by Fe2+ exposure. I propose that this 
mechanism is a contributing factor in the pathogenesis of MLIV. It should be noted that since 
TRPML1 inactivation has been suggested in a range of diseases involving lipid metabolism, this 
mechanism is possibly a contributing factor in the pathogenesis of other diseases outside of MLIV 
(203).  
3.2 RESULTS 
It has previously been shown that TRPML1 is responsible for the transport of Fe2+ as TRPML1 
loss has been associated with the buildup of Fe2+ (58). However, the impact of Fe2+ dysregulation 
in TRPML1-deficient cells has not been comprehensively described. Under normal conditions, it 
is suggested that TRPML1 functions to release lysosomally accumulated Fe2+ into the cytoplasm 
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(58). There it is then scavenged by ferritin and exported out of the cells though ferroportin (216). 
Since Fe2+ catalyzes ROS production, I propose that Fe2+ retention in TRPML1-deficient cells 
leads to ROS production (99). If this model is correct, then: 1) the effects of Fe2+ exposure will 
potentiate the cellular consequences of TRPML1 loss, and 2) the addition of the ROS antioxidant 
α-tocopherol should eliminate such consequences.  
3.2.1 ROS are generated in RPE1 cells in response to TRPML1 deficit 
In these studies, I used human RPE1 cells that were immortalized with hTERT. Among several 
reasons for choosing this cell type was the fact that MLIV involves ocular abnormalities. While 
most abnormalities involve corneal and conjunctiva epithelial, some damage to retinal epithelial 
does occur in MLIV (40,217). In order to test the effects of TRPML1 loss, two siRNA probes were 
utilized as previously described (189,190). These probes, TRPML1 959 siRNA and TRPML1 745 
siRNA, produced consistent results, which are discussed throughout this report. In RPE1 cells, 
TRPML1-KD with TRPML1 959 siRNA resulted in the loss of 87.5±1.7% of MCOLN1 mRNA, 
while TRPML1 745 siRNA resulted in the loss of 93.8±1.2% of MCOLN1 mRNA (Figure 6A). 
Towards testing the cell-wide effects of TRPML1 loss and aggravation by Fe2+ accumulation, I 
exposed control and TRPML1-KD cells to 100 µM Fe2+ for the period of 24 to 48 hours. I subjected 
these cells to a series of tests aimed at detecting ROS and cellular dysfunctions induced by ROS.  
The first set of experiments focused on answering whether TRPML1-deficient cells 
produce ROS and whether Fe2+ exposure elevates ROS levels when cells lack the TRPML1 ion 
channel. When cells are challenged with elevated ROS levels, the cytoprotective transcription 
factor, nuclear factor erythroid 2-related factor 2 (Nrf2) is activated, which in turn activates the 
transcription of several genes involved in cytoprotection from oxidative stress and inflammation 
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(148). Expression levels of mRNA coded by such genes have previously been used as a readout of 
ROS production and oxidative stress. I selected heme oxygenase-1 (HMOX1), which is a well-
characterized gene known to be transcriptionally regulated by Nrf2 in response to oxidative stress 
(78). Cells were transfected with control and TRPML1 siRNA and treated with chemicals prior to 
measurement of HMOX1 mRNA levels using quantitative PCR.  
When RPE1 cells were incubated with the positive control tert-Butyl hydroperoxide 
(TBHP), HMOX1 mRNA was upregulated, indicative of a strong response to oxidative stress 
(Figure 7A). Analysis of HMOX1 mRNA levels in TRPML1 959-KD cells indicate that HMOX1 
mRNA levels were consistently increased, averaging 341.1±60.6% more than the levels detected 
in control cells (Figure 7B, p<0.0001). Furthermore, exposure of TRPML1 959-KD cells to Fe2+ 
for 48 hours caused a significant increase in HMOX1 mRNA levels, far exceeding the levels 
detected in TRPML1 959-KD cells. In Fe2+-treated TRPML1-KD cells, HMOX1 mRNA levels 
averaged 1068.4±99.1% more than levels detected in control untreated cells (p<0.0001). 
Transfection with TRPML1 745 siRNA resulted in a significant loss of HMOX1 mRNA, but 
exposure to Fe2+ significantly upregulated HMOX1 mRNA levels in these cells (Figure 8A). While 
exposure of control-KD cells to 100 µM Fe2+ for 48 hours did not result in a statistically significant 
change in HMOX1 mRNA levels (10.38±1.9% gain), Fe2+ treatment with both TRPML1 siRNA 
constructs resulted in statistically significant changes in HMOX1 mRNA levels (Figure 8B, 
159.8±19.1% gain, p<0.001 for TRPML1 959 siRNA and 110.7±21.3% gain, p<0.005 for 
TRPML1 745 siRNA). This data suggests that exposure to Fe2+ potentiates the production of ROS 
in TRPML1-deficient cells. 
Autophagic issues were previously shown in TRPML1-/- patient skin fibroblasts (24,218). 
Such issues were linked to a buildup of dysfunctional mitochondria (24,218). Since the latter can 
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produce ROS, I sought to answer whether or not autophagic deficits impact ROS buildup in 
TRPML1-KD cells. For this purpose, I treated RPE1 cells with the autophagy inhibitor 3-
Methyladenine (3-MA) and analyzed HMOX1 mRNA levels. Prior to analysis of HMOX1 mRNA, 
I confirmed the effectiveness of the 3-MA treatment and the effects of TRPML1-KD on autophagic 
flux by measuring the ratio of LC3B-II and LC3B-I proteins (Figure 9A) (192,219). Western blot 
analysis was used to measure this ratio and Figure 9B shows that both 3-MA and TRPML1-KD 
have reduced ratios of LC3B-II/LC3B-I, suggesting that both of these conditions alter normal 
autophagic flux. A reduction in this ratio can indicate reduced number of autophagosomes, delays 
in trafficking to the lysosome, reduced fusion with the lysosome, or impaired proteolytic activity. 
While reduced ratios in 3-MA treatments are likely due to a decrease in autophagosomal number, 
the exact cause of reduced autophagic flux in response to TRPML1 959-KD is unknown. To 
determine if an autophagic deficit alone was responsible for the generation of ROS, HMOX1 
mRNA levels were then analyzed. Figure 7B shows that TRPML1-KD induces an increase in 
HMOX1 mRNA, while 3-MA does not, which indicates that general inhibition of autophagic flux 
alone is not enough to induce the production of ROS.  
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Figure 6 siRNA mediated TRPML1-KD in RPE1 cells 
MCOLN1 mRNA expression assessed by qPCR in RPE1 cells in control-KD, TRPML1 959-KD, 
and TRPML1 745-KD conditions. Cells were exposed to siRNA for 72 hours prior to isolation of 
RNA. Data were normalized to values detected in untreated control-KD cells, which were taken 
as 100%. Data are means ± S.E.M. from three or more experiments for all conditions, ** P<0.01 
between values indicated by brackets.  
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Figure 7 TRPML1-KD in RPE1 cells leads to ROS production 
(A) HMOX1 mRNA expression assessed by qPCR in control and TRPML1-KD cells exposed to 
200 μM TBHP for 4 hours. Data were normalized to values detected in untreated control-KD cells, 
which were taken as 100%. (B) HMOX1 mRNA expression in control and TRPML1-KD cells 
exposed to 100 μM Fe2+ for 48 hours or 100 nM α-Toc for 24 hours. Control-KD cells were also 
exposed to 2.5 mM 3-MA for 24 hours prior to analysis. Data were normalized to values detected 
in untreated control-KD cells, which were taken as 100%. Data are means ± S.E.M. from three or 
more experiments for all conditions, ** P<0.01 between values indicated by brackets.  
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Figure 8 TRPML1-KD with Fe2+ leads to increased levels of ROS production 
(A) HMOX1 mRNA expression assessed by qPCR in control and TRPML1 745-KD cells exposed 
or not to 100 μM Fe2+ for 48 hours. (B) The percentage gain of HMOX1 mRNA expression 
between Fe2+ and untreated cells. Data were normalized to values detected in untreated control-
KD cells, which were taken as 100%. Data are means ± S.E.M. from three or more experiments 
for all conditions, ** P < 0.01. 
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To assess the impact of ROS on membrane lipid peroxidation in RPE1 cells, the fluorescent 
ratiometric probe BODIPY® 581/591 C11 undecanoic acid was used. When this fatty acid probe 
reacts with radicals generated by oxidative stress, there is a shift in fluorescence of the fluorophore 
from red to green, indicative of lipid peroxidation (154). Figure 10 shows that lipid peroxidation 
is significantly upregulated in TRPML1 959-KD cells both unexposed and exposed to Fe2+ for 24 
hours compared to control-KD. I was unable to detect a statistically significant increase in 
oxidation between Fe2+-treated and untreated TRPML1 959-KD cells, as the degree of oxidation 
was relatively high in untreated TRPML1 959-KD cells initially. However, compartmentalization 
of oxidized lipids in Fe2+-treated TRPML1 959-KD cells is evident (Figure 10). 
3.2.2 TRPML1-KD mediates changes in mitochondrial function and morphology 
One of the main targets of oxidative damage is mitochondria (220). Oxidation of mitochondrial 
lipids was previously shown to lead to the loss of ΔΨm, which is a pre-apoptotic event (170,210-
214,220). To test whether TRPML1 loss causes mitochondrial depolarization, I measured changes 
in ΔΨm using the fluorescent dye JC-1. As a positive control, RPE1 cells were exposed to CCCP, 
a proton gradient uncoupler, which decreased ΔΨm by 78.9±0.5% relative to control (Figure 11, 
p<0.0001). Measurement of ΔΨm in TRPML1-KD cells indicated that loss of TRPML1 induced a 
significant decrease in ΔΨm for both TRPML1 siRNA constructs. When compared to control-KD, 
TRPML1 959 siRNA decreased ΔΨm by 13.1±1.8%, while TRPML1 745 siRNA decreased ΔΨm 
by 19.6±4.4% (Figure 11, p<0.0001 for both). Additionally, exposure of TRPML1-KD cells to 
Fe2+ for 48 hours potentiated the loss of ΔΨm compared to untreated control-KD for both siRNA, 
as TRPML1 959 siRNA with Fe2+ decreased ΔΨm by 27.2±1.9% and TRPML1 745 siRNA with 
Fe2+ decreased ΔΨm by 34.0±2.2% (Figure 11, p<0.0001 for both). Such a decrease was 
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undetectable in control-KD cells, as Fe2+ only decreased ΔΨm by 4.0±2.3% (Figure 11, not 
significant). To rule out the possibility that loss of ΔΨm was inducing apoptosis in these cells, 
induction of apoptosis was analyzed. Using both annexin V staining via flow cytometry and 
Caspase 3 activity, it was determined that apoptosis was not significantly activated in any of my 
siRNA-KD conditions (Figure 12 and Figure 13).  
Our lab has previously shown that in cells affected by LSDs, including MLIV, 
mitochondria are fragmented (24,218). I attributed this phenotype to the buildup of effete 
mitochondria, which are not processed in time due to an autophagy block in cells affected by LSDs. 
Since suppressed autophagy is a significant factor in explaining pathogenesis of LSDs 
(49,200,209,221-224), this model connected lysosomal deficiencies in MLIV to autophagy, to 
deficits in mitochondrial function, and to cell death. The original force causing mitochondrial 
fragmentation under these conditions remained unidentified. Specifically, it was not clear whether 
fragmentation is a passive result of mitochondrial aging and delayed cleanup, or whether it is 
caused by lysosomal deficiencies in LSDs. Towards answering this question, I compared 
mitochondrial phenotypes in control cells and cells acutely deficient of the lysosomal ion channel 
TRPML1. In agreement with the previously published data, TRPML1-KD caused a punctate 
mitochondrial phenotype. Figure 15A shows confocal images of RPE1 cells stained with 
Mitotracker Green® FM. While mitochondria in control-KD cells look like long threads, such 
threads are broken in both TRPML1 959-KD and TRPML1 745-KD cells (Figure 15A and Figure 
16A).  
 
 
 63 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 9 3-MA and TRPML1 959-KD alter autophagic flux in RPE1 cells 
(A) Representative western blot indicates processing of LC3B. Expression levels of LC3B-I, 
LC3B-II, and actin were analyzed following control-KD, TRPML1 959-KD, treatment with 20 
μM Chloroquine (CQ) for 12 hours, or 2.5 mM 3-MA for 24 hours. Actin was used as a loading 
control. (B) Autophagic flux was measured by quantifying the ratio of the band intensities of 
LC3B-II and LC3B-I, which reflects autophagic flux. Levels of LC3-II and LC3-I were normalized 
to actin loading control.  
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Figure 10 TRPML1-KD induces lipid peroxidation in RPE1 cells 
(A) Confocal images of RPE1 cells, 72 hours post transfection with control or TRPML1 siRNA, 
exposed to 100 µM Fe2+ for 24 hours. Cells were stained with 3 µM of C11-BODIPY undecanoic 
acid. n=3. Scale bar corresponds to 50 µm. Note increased green stain in TRPML1-KD cells 
exposed to Fe2+, compared to control cells exposed to Fe2+. Arrowheads indicate accumulation of 
oxidized lipids. (B) Quantification of oxidation% of C11-BODIPY, where oxidation% = 100%× 
Green/(Green + Red), where Green and Red are pixel values of images recorded with an excitation 
of 488 nm and emissions at 498-544 nm for peroxidated probe and 580-620 nm for the intact probe 
(154). Data were normalized to values detected in untreated control-KD cells, which were taken 
as 100%. Data obtained from 3 separate experiments of 5 images containing 3 or more cells, * 
represents p<0.05.  
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Figure 11 Mitochondrial depolarization is induced in TRPML1-KD cells and is potentiated 
by exposure to Fe2+ 
(A) Fluorometric analysis of JC-1 fluorescence in control and TRPML1 959 and 745-KD cells 
exposed to 100 µM Fe2+ for 48 hours. 10 µM CCCP for 15 minutes was used as a positive control. 
Data were normalized to values detected in untreated control-KD cells, which were taken as 100%. 
n=5. * represents p<0.01. 
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Figure 12 TRPML1-KD is not associated with binding of Annexin V 
(A) Positive control for cell death induced by 100 nM Staurosporine. (B-E) Cells transfected with 
control (B, C) and TRPML1 959-siRNA (D, E), untreated (B, C) and treated with Fe2+ (D, E). 
Note an increase in stain positive for Propidium Iodide and Annexin V, indicating late apoptosis 
in cells treated with Staurosporine.  
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Figure 13 TRPML1 deficiency in RPE1 cells does not induce activation of Caspase 3 
(A) Apoptosis was measured using the EnzChek Caspase 3 Apoptotic assay in RPE1 cells 72 hours 
post transfection with control or TRPML1 siRNA. Cells were also treated with 100 µM Fe2+ for 
48 hours prior to analysis. As a positive control, cells were treated with 100 nM Staurosporine for 
12 hours prior to analysis. Caspase 3 activity is shown as AMC fluorescence and as a % of 
untreated control cells. n=3. ** represents p<0.01 
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To quantify the differences in mitochondrial morphology between control and TRPML1-
KD cells, I utilized previously defined characteristics of mitochondrial morphology (225,226). I 
used two descriptors of mitochondrial shape: aspect ratio (AR) and form factor (FF), as both give 
a full picture of differences in the structure of mitochondrial networks. My method of analysis is 
described in Figure 14. All images used in this analysis were obtained using Mitotracker Green® 
FM, since this stain does not depend on membrane potential and gives an accurate representation 
of shape. Image analysis was performed in ImageJ. The particle counting function of ImageJ was 
used to yield mitochondrial number as well as specific characteristics of mitochondria including 
area, perimeter, AR, and FF.  
AR is a ratio that represents mitochondrial length. Elongated objects have higher AR than 
shorter circular objects and thus AR is frequently used to compare mitochondrial lengths in cells 
with well-ordered mitochondrial network, such as neurons. Figure 15B shows AR comparisons 
between control and TRPML1 959-KD cells, in addition to treatments that will be described below. 
In TRPML1 959-KD cells a statistically significant decrease in length was evident, as AR 
decreased by 15.4±1.5% relative to control (p<0.0005).  
FF was used as a measurement of mitochondrial network complexity as it took into account 
the degree of mitochondrial branching and overlap. Healthy mitochondrial networks are often 
longer and more complex, thus individual mitochondria branch more and overlap with each other; 
resulting in higher FF. While unhealthy, shorter mitochondria are less likely to overlap and branch. 
Therefore higher FF is indicative of healthy mitochondria. FF is defined by the formula: FF=P2 / 
π × S, where P is perimeter, and S is area of the particle. Figure 15C compares FF between control 
and TRPML1 959-KD cells, in addition to treatments that will be described below. In TRPMl1 
959-KD cells a statistically significant decrease in complexity was evident, as FF decreased by 
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34.9±3.2% relative to control (p<0.0005). In summary, these data show that TRPML1 959-KD 
leads to shorter mitochondria with significantly less complexity in regards to branching and 
overlap.  
Figure 15A shows that exposure of TRPML1 959-KD cells to Fe2+ for 24 hours leads to a 
more pronounced punctate mitochondrial phenotype than in untreated control-KD or TRPML1 
959-KD cells. Quantification of this difference in Figure 15B indicates that mitochondrial length 
(AR) in TRPML1 959-KD cells treated with Fe2+ is significantly decreased compared to both 
untreated control-KD (22.0±1.2% decrease, p<0.0001) and TRPML1 959-KD cells (7.81% 
decrease, p<0.05). FF decreased in Fe2+-treated TRPML1 959-KD cells, although this difference 
was not statistically significant compared to control-KD cells (Figure 15C). I attribute this to the 
fairly high degree of fragmentation and reduction in branching already present in untreated 
TRPML1 959-KD cells.  
Analysis of AR and FF in TRPML1 745-KD cells was not performed, however the 
morphological trend observed was similar to TRPML1 959-KD but was much less dramatic 
(Figure 16A). The effects of TRPML1 745 siRNA and TRPML1 959 siRNA on mitochondrial 
morphology may be correlated with lower HMOX1 mRNA levels, indicative of lower ROS levels, 
upon TRPML1 745-KD.  
 
 70 
 Figure 14 Mitochondrial morphology image analysis 
(A) Confocal images of RPE1 cells stained with the mitochondrial marker Mitotracker Green® 
FM. In this example, cells 72 hours post transfection with control siRNA are shown. Outlined are 
cells selected for further analysis. They are complete cells, with defined mitochondria, present in 
similar focal planes. (B) An example of a cell selected for analysis. (C) Binary image of the cell 
from panel B. (D) Outcome of the “particle counting” function of ImageJ applied to the same cell. 
Red numbers indicate individual particles. 
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 Figure 15 Mitochondrial morphology changes as a function of TRPML1 status, Fe2+ 
treatment, and ROS 
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(A) Confocal images of RPE1 cells stained with the mitochondrial marker MitoTracker™ Green 
FM. At 72 hours post-transfection with TRPML1 959 siRNA, cells were exposed to 100 µM Fe2+ 
or 100 nM α-Toc for 24 h. Scale bar, 20 µm. Brightness was adjusted in some images for better 
presentation. n=3. (B and C) Statistical analysis of AR (B) and FF (C) of mitochondria from 
untreated Fe2+ or α-Toc treated RPE1 cells transfected with control siRNA and TRPML1 959 
siRNA. Data were normalized to values detected in untreated control-KD cells, which were taken 
as 100%. For control-KD, data were obtained from 835 mitochondria from 23 cells; for TRPML1 
959-KD, data were obtained from 1500 mitochondria from 22 cells; for TRPML1 959-KD with 
Fe2+, data were obtained from 1434 mitochondria in 27 cells; for TRPML1 959-KD with α-Toc, 
data were obtained from 1313 mitochondria in 23 cells. Results are ± S.E.M.; *P<0.05 and 
**P<0.01. 
 
Figure 16 TRPML1 745-KD induces changes in mitochondrial morphology 
Confocal images of RPE1 cells stained with mitochondrial marker MitoTracker™ Green FM. At 
72 hours post-transfection with TRPML1 745 siRNA, cells were exposed to 100 µM Fe2+ or 100 
nM α-Toc for 24 h. Scale bar, 20 µm. n=3.  
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3.2.3 α-Tocopherol as a potential therapeutic treatment for TRPML1-deficient RPE1 
cells 
To determine if the increase in ROS levels due to the loss of TRPML1 is reversible, TRPML1-
deficient cells were subjected to antioxidant treatment. The antioxidant α-Toc was selected for use 
as it is known to be lipophilic in nature and thus associates with lipoproteins, fats, and cell 
membranes and works to protect the polyunsaturated fatty acids from peroxidation reactions (227). 
Since lipid peroxidation occurred as a result of TRPML1 loss, I hypothesized that the use of α-Toc 
may reduce the ROS burden. Figure 7B shows that incubation with 100 nM α-Toc for 24 hours in 
TRPML1 959-KD cells reduced the expression levels of HMOX1 mRNA compared to untreated 
TRPML1 959-KD cells alone (68.2% decrease, p<0.01). 
If mitochondrial fragmentation is a direct consequence of ROS production due to Fe2+ 
buildup in lysosomes in TRPML1-deficient cells, I predict that ROS reduction should reverse the 
mitochondrial fragmentation, as ROS reduction was shown above to decrease HMOX1 mRNA 
levels. While mitochondria in control-KD cells were unaffected by α-Toc treatment, α-Toc 
significantly reversed the punctate mitochondrial phenotype in TRPML1 959-KD cells (Figure 
15A). This reversion of mitochondrial fragmentation is supported by a significant increase in 
mitochondrial length in TRPML1 959-KD cells treated with α-Toc, as AR was 8.8% higher than 
TRPML1 959-KD cells alone (Figure 15B, p<0.05). Additionally, mitochondrial complexity 
increased significantly with the addition of α-Toc to TRPML1 959-KD cells, as FF was 19.8% 
higher than TRPML1 959-KD alone (Figure 15C, p<0.05). In conjunction with Fe2+ exposure in 
TRPML1 959-KD cells, these results strongly suggest that the loss of TRPML1 drives 
mitochondrial fragmentation and ROS generation that may play a strong role in the pathogenesis 
of MLIV. The reversibility of these phenotypes induced by TRPML1-KD indicates that 
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antioxidant therapy may alleviate some aspects of MLIV pathogenesis. While α-Toc successfully 
reduced the oxidative stress burden and reversed the mitochondrial punctate phenotype, it remains 
to be determined if α-Toc treatment can alleviate other aspects of TRPML1 loss or if it can improve 
channel activity in TRPML1 mutants.  
3.2.4 ROS in TRPML1-deficient cells colocalize with lysosomes 
In order to determine if Fe2+ accumulation in lysosomes of TRPML1-deficient cells promote ROS 
production within the lysosome, I examined the localization of ROS within my RPE1 model 
system. While the methods available to determine ROS localization are currently limited, I was 
able to pinpoint the site of ROS production in my model. Using carboxy-H2DCFDA, a fluorescent 
ROS sensitive probe, I determined that the signal colocalized with lysosomes (Figure 17). To 
support this data, and to rule out the possibility that ROS are generated/localized to the 
mitochondria, I analyzed mitochondria in TRPML1-deficient cells for the presence of superoxide 
using the dye MitoSOX™ Red. Supporting my hypothesis that ROS are produced in the lysosome 
as a result of Fe2+ accumulation in cells deficient of TRPML1; no mitochondrial superoxide 
production was observed in any condition except the positive control (Figure 18). As more ROS 
probes become available I will be able to better support my finding and my hypothesis that ROS 
in this model are lysosomally localized.  
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Figure 17 ROS in Fe2+ treated TRPML1-deficient RPE1 cells colocalizes with lysosomes 
(A) Confocal images of RPE1 cells, 72 hours post transfection with control or TRPML1 959 
siRNA, exposed to 100 µM Fe2+ for 24 hours. Cells were stained with 25 µM of carboxy-
H2DCFDA. n=3. Scale bar corresponds to 50 µm. (B) Plot profiles of cells sectioned for analysis 
in panel A. 
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Figure 18 ROS in TRPML1 deficient RPE1 cells are not localized to mitochondria 
(A) Mitochondrial superoxide generation was measured in live RPE1 cells transfected with control 
or TRPML1 959-siRNA for 72 hours prior to imaging. Cells were also treated with 100 µM Fe2+ 
or 100 nM α-Toc for 24 hours prior to imaging. As a positive control, cells were treated with 200 
µM TBHP for 4 hours prior to imaging. Cells were loaded with MitoSOX™ Red and 
MitoTracker® Green FM according to manufacturer’s instructions. (B) Quantification of changes 
in superoxide production as a direct reflection of mean red fluorescence intensity expressed as % 
of control. n=3.  
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 Figure 19 Model of TRPML1-deficiency in RPE1 cells induces ROS and mitochondrial 
fragmentation 
(A) Under normal conditions, Fe2+ enters the lysosome via endocytosis of Fe2+ bound proteins. 
The proteins are degraded and Fe2+ is transported to the cytoplasm via TRPML1 ion channel. In 
the cytoplasm, Fe2+ binds to low affinity chelators. Under these conditions, mitochondria remain 
elongated. (B) In MLIV cells lacking TRPML1, Fe2+ that would normally be transported to the 
cytoplasm, accumulates in the lysosome and catalyzes Fenton reactions resulting in the production 
of ROS. ROS oxidize lipids, which may permeabilize the lysosomal membrane, allowing ROS to 
access the cytosol and induce mitochondrial fragmentation and loss of ΔΨm.  
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3.3 DISCUSSION 
Whereas TRPML1 conductance properties and regulation are well understood, the functional 
impact of TRPML1 activity on the endocytic pathway and the cell as a whole is largely unclear. A 
popular explanation pins its function to Ca2+ release events that drive membrane fusion in the 
endocytic pathway (203). This explanation is supported by the fact that TRPML1 conducts Ca2+. 
On the other hand, TRPML1 is also known to conduct Fe2+ and Zn2+, and accumulation of these 
metals has been shown in TRPML1-deficient cells (58,88,103). My results provide additional 
insight into the pathogenesis of MLIV and suggest that TRPML1 regulates transition metal 
homeostasis within the lysosome in addition to processes beyond the lysosome.  
Although our understanding of TRPML1’s functional impact beyond the lysosome is 
limited, there is a fairly well developed body of data connecting TRPML1 loss to autophagy 
deficits in MLIV patient fibroblasts and mouse tissues (49,54). As discussed earlier, an important 
question remains whether or not cell deterioration in TRPML1-deficient cells, and ultimately 
MLIV, is a passive outcome of the loss of degradative and absorptive functions of the lysosome. 
An alternative explanation suggests that the loss of TRPML1 may promote active cell damaging, 
such as the mitochondrial fragmentation I see here. Identification of these processes may point 
towards additional avenues of therapeutic approaches for MLIV. It should be noted that TRPML1 
is blocked by sphingomyelins and a TRPML1 component was proposed in diseases associated 
with sphingomyelin accumulation or mishandling (203). It is, therefore, possible that pathological 
effects of TRPML1 loss discussed here are applicable to a range of conditions.  
Here I showed that TRPML1 loss is associated with mitochondrial fragmentation. The 
relatively short time to development and TRPML1-specificity of this phenotype suggests that this 
phenotype is an active event caused by the loss of TRPML1 and perhaps further aggravated by the 
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induced lysosomal deficits and/or Fe2+ accumulation associated with MLIV. The fact that this 
fragmentation is reversed by ROS reduction with an antioxidant is new. It suggests that ROS 
generated from TRPML1-deficient cells damages mitochondria. This is a unique observation 
connecting TRPML1 to processes outside the lysosome. ROS generation in my model is supported 
by qPCR experiments and lipid peroxidation assays, while ROS localization within lysosomes is 
supported by carboxy-H2DCFDA assays. While new techniques arise to analyze ROS at the 
cellular level, specifics like where ROS are produced and where ROS are acting on proteins, lipids, 
and DNA can be determined.  
Based on these results, and the previously published evidence of TRPML1 permeability to 
Fe2+ and Zn2+, this supports the idea that TRPML1 is a lysosomal divalent cation channel, whose 
function is to regulate - directly or not - the distribution of transition metals between lysosomes 
and the cytoplasm. In the context of the experimental model used in this study, cell overload with 
transition metals and the loss of TRPML1 function likely resulted in metal accumulation in the 
lysosome. This speculation is supported by previously published data on Fe2+ and Zn2+ buildup in 
the lysosomes of TRPML1-deficient cells (58,88,103). A unique aspect of my study is the evidence 
that such a buildup is associated with ROS production. It appears that the generation of ROS in 
my system is strong enough to induce structural and physiological changes in mitochondria (Figure 
19). Based on the fact that Fe2+ aggravated every aspect of TRPML1-KD phenotype discussed 
here, I propose that Fe2+ entrapment in the lysosomes and the resulting ROS production in 
TRPML1-KD cells are the key factors of cell damage in these cells. Autophagy inhibition prevents 
mitochondrial recycling and could lead to secondary damages such as ROS production. However 
my experiments using 3-MA to inhibit autophagic flux (Figure 6B) argue against this being the 
sole cause of ROS generation in my model.  
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Until the functional significance of the proposed model is tested in TRPML1-deficient 
animals, it is difficult to determine the potential significance of antioxidant treatment for ultra-
structural and clinical aspects of MLIV pathogenesis. It does, however, provide a novel and 
specific avenue towards directly testing mechanisms, as well as developing approaches to alleviate 
symptoms of MLIV.  
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4.0  OXIDATIVE STRESS INDUCED BY TRPML1 DEFICIENCY ALTERS 
EXPRESSION OF REGULATORS OF MITOCHONDRIAL DYNAMICS AND 
REDUCES MITOCHONDRIAL METABOLISM 
The work discussed in this Chapter is unpublished data of which I performed all of the experiments 
except for the microarray assay, which was performed by a previous graduate student in our lab 
Dr. Grace Colletti, and the JC-1 assay with GDAP1-KD, which was performed by a current 
graduate student in our lab, Karina Peña. Part of this work stems from a collaborative effort with 
Dr. Susan Slaugenhaupt’s lab at Harvard Medical School. 
4.1 INTRODUCTION 
TRPML1 is a lysosomal ion channel encoded for by the gene MCOLN1. Mutations in the gene are 
associated with the lysosomal storage disorder Mucolipidosis type IV (MLIV) (34). MLIV is a 
neurodevelopmental and neurodegenerative disease that more recently was found to induce 
activation of microglia (41). MLIV is characterized by the presence of electron dense storage 
bodies. Very little is known about the pathogenesis of MLIV, as the role of the ion channel 
TRPML1 is still being determined. Recent advances in TRPML1 biology indicate that it acts as a 
Ca2+ release channel to promote fusion of late endosomes and lysosomal membranes and has a 
role in transition metal homeostasis, as it functions to release Fe2+ and Zn2+ into the cytosol from 
the lysosomal lumen (23,58,62,88,103).  
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In addition to TRPML1s role in transition metal homeostasis, I recently indicated that the 
role of TRPML1 in the cell extends beyond the lysosome as it affects several parameters of 
mitochondrial function, including mitochondrial morphology, induction of ROS in response to the 
loss of TRPML1, which induces lipid peroxidation and mitochondrial depolarization(23). 
However, in disagreement with MLIV studies and some other model systems I do not observe any 
cell death (23). While changes in these parameters lend insight into the mechanism of MLIV 
pathogenesis, the molecular mechanisms regulating mitochondrial fragmentation in TRPML1-
deficient cells are not known. Previous work in MLIV patient fibroblasts have indicated that 
autophagic deficits lead to the buildup of effete mitochondria, which is associated with loss of Ca2+ 
buffering capacity that could possibly lead to pro-apoptotic effects (24). As my previous results 
ruled out the possibility that mitochondrial fragmentation is the result of autophagic deficit, this 
scenario is not likely the sole cause of mitochondrial fragmentation.  
To delineate the events associated with loss of TRPML1, production of ROS, 
mitochondrial permeabilization, and mitochondrial fragmentation I first confirmed the presence of 
oxidative stress in the MLIV mouse model. Next I examined alterations in gene expression upon 
the loss of TRPML1 to determine if any mitochondrial proteins are altered by the loss of TRPML1. 
Since our lab has previously performed a microarray analysis in HeLa cells after a 48 hour 
knockdown of TRPML1, I first examined gene expression changes in that data, and then performed 
qPCR analysis to confirm gene expression in my RPE1 model system (Unpublished data). Upon 
identification of any possible target genes, I confirmed that changes in gene expression were 
specific to the loss of TRPML1. To do this, I compared the results to a microarray performed in 
HeLa cells transfected with siRNA for the enzyme palmitoyl-protein-thioesterase 1 (PPT1), a gene 
mutated in infantile neuronal ceroid lipofuscinosis (INCL), another LSD (228). Additionally I ran 
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qPCR experiments on RPE1 cells transfected with PPT1 siRNA. I also confirmed my findings in 
MLIV patents fibroblasts. The potential candidate gene, GDAP1 was identified. The identification 
of GDAP1 as a candidate that links oxidative stress to mitochondrial fragmentation has provided 
additional insight into the regulation of MLIV pathogenesis.  
4.2 RESULTS 
4.2.1 RPE1 cell culture model of oxidative stress as a factor in MLIV pathogenesis 
extends to the MLIV mouse model 
Recent data from our lab indicates that the loss of TRPML1 in RPE1 cells results in the production 
of ROS (23). To confirm this phenotype in a more physiologically relevant model system, qPCR 
was performed on samples isolated from MCOLN1-/- and MCOLN1+/+ mouse brain isolated at 2 
and 6 months of age. This study was performed in a doubly blind manner to eliminate bias. As a 
read out of oxidative stress, I once again examined the mRNA levels of genes 
antioxidant/cytoprotective genes that are transcriptionally regulated by the master regulator of 
antioxidant and cytoprotective genes, Nrf2 (146,147). Figure 20 shows the qPCR analysis of HO-
1 and NQO1 mRNA abundance in mouse brains at 2 and 6 months of age. Figure 20 indicates that 
HO-1 mRNA levels are significantly increased at both 2 and 6 months of age, while NQO1 is 
significantly upregulated only after 6 months of age. These results confirm the oxidative stress 
data obtained from my TRPML1-deficient RPE1 model. 
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4.2.2 Oxidative stress in TRPML1-deficient cells alters gene expression of a 
mitochondrial fission factor 
To obtain a general overview of gene regulation in response to the down regulation of TRPML1 
in HeLa cells, as an attempt to identify a candidate gene inducible by ROS and responsible for 
initiating mitochondrial fragmentation I examined the top up and down regulated genes from a 
microarray analysis on TRPML1-48 hour-KD cells. The 34 most up or down regulated genes, their 
cellular role, and their cellular localization are listed in Table 3. One of the genes, GDAP1, looked 
like the best possible candidate to fit my description, as it is activated by cellular oxidative stress 
and induces mitochondrial fragmentation. As discussed in section 1.5.3, GDAP1 is the ganglioside 
induced differentiation associated protein 1, which is involved in mitochondrial fission and is 
localized to the OMM (65,183,185). Interestingly, GDAP1 was first identified in a study where 
extracellular gangliosides were added to cell culture to induce differentiation (229). Over 
expression of GDAP1 has been shown to induce mitochondrial fragmentation, while not activating 
apoptosis (183,185). Mutations in GDAP1 are associated with both dominant and recessive forms 
of Charcot-Marie-Tooth (CMT) neuropathies (185). GDAP1 is characterized as a new member of 
the glutathione S-transferase (GST) family based on sequence similarity (182). Whether or not it 
has GST activity is not known, but recent data indicates that GDAP1 expression was critical for 
protection against oxidative stress in response to low glutathione levels, as cells expressing mutant 
GDAP1 did not survive (187). This result indicates that GDAP1 may have a protective effect under 
oxidative stress conditions. Recent work with GDAP1L1, a GDAP1 paralog, suggests that 
GDAP1-family members act in a protective manner against stress caused by elevated levels of 
oxidized glutathione (185).  
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 To confirm that GDAP1 is actually expressed at elevated levels in a TRPML1 deficient 
model, I examined GDAP1 mRNA expression in conjunction with HMOX1 levels in MLIV patient 
fibroblasts. Figure 21 shows significantly elevated levels of GDAP1 and HMOX1 mRNA in the 
MLIV patient. This result indicates that loss of TRPML1 does indeed induce oxidative stress, 
which is somehow correlated to the expression of GDAP1.  
 To confirm that GDAP1 is responsible for the mitochondrial phenotypes I observed in the 
TRPML1-deficient RPE1 cell model, I examined expression of two genes that maintain 
mitochondrial dynamics, GDAP1 and MFN1. To ensure that the results I saw were specific to loss 
of TRPML1, I compared the results with PPT1-deficient RPE1 cells. Figure 22 showed the 
effective siRNA modulation of MCOLN1, GDAP1, and PPT1. Surprisingly, Figure 23A indicated 
that TRPML1-KD in RPE1 cells results in down regulation of MFN1. While this result cannot 
currently be explained, it is rather interesting as down regulation of MFN1 would support a shift 
in mitochondrial dynamics towards fission. As I expected, in agreement with MLIV patient 
fibroblasts, Figure 23B indicated that TRPML1 KD in RPE1 cells results in up regulation of 
GDAP1. Loss of PPT1 in RPE1 cells did not result in significant changes in either MFN1 or 
GDAP1. 
 To confirm that GDAP1 upregulation occurred secondary to oxidative stress induced by 
TRPML1 loss in RPE1 cells, I utilized the antioxidant α-tocopherol. Treatment with α-tocopherol 
reversed the GDAP1 upregulation indicating that GDAP1 is upregulated in response to the 
oxidative stress burden in TRPML1 deficient cells. Supporting my hypothesis that a candidate 
gene is activated in response to oxidative stress induced by loss of TRPML1.  
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Figure 20 Oxidative stress in brain isolated from MLIV mouse model 
(A) Analysis of HO-1 and NQO1 mRNA expression by qPCR. mRNA was obtained from whole 
brain homogenates of Mcoln1+/+ and Mcoln1-/- mice at 2 or 6 months of age. Four separate samples 
were analyzed in a double blind manner for each condition. Data are normalized to Mcoln1-/-, 
which was considered 100%. HO-1 and NQO1 mRNA levels were normalized to the house-
keeping gene RPL32. * represents p<0.05.  
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Table 3 Up and down regulated genes from microarray analysis of TRPML1-deficient HeLa 
cells 
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Figure 21 Oxidative stress in MLIV patient fibroblasts induces transcription of GDAP1, a 
key player in mitochondrial fragmentation 
(A) qPCR analysis of HMOX1 and (B) GDAP1 mRNA levels in fibroblasts isolated from an MLIV 
patient and related control, shown as % of control. n=2, ** indicates P<0.01.  
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Figure 22 siRNA modulation of TRPML1, GDAP1, and PPT1 in RPE1 cells 
(A) qPCR analysis of MCOLN1 mRNA levels in RPE1 cells transfected with control, TRPML1 
959, or TRPML1 745-siRNA. (B) qPCR analysis of GDAP1 mRNA levels in RPE1 cells 
transfected with control or GDAP1 siRNA. (C) qPCR analysis of PPT1 mRNA levels in RPE1 
cells transfected with control or PPT1 siRNA. For all transfections, RNA was isolated 72 hours 
post transfection. Data shown as % of control-KD cells, n=3, ** indicates P<0.01. (D) Western 
blot analysis of PPT1 protein levels in cells transfected with control and PPT1 siRNA. 
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Figure 23 Changes in MFN1 and GDAP1 mRNA levels are specific to TRPML1 functional 
status in RPE1 cells and not general lysosomal dysfunction 
(A) qPCR analysis of MFN1 and (B) GDAP1 mRNA levels in RPE1 cells transfected with control, 
TRPML1 959, or PPT1 siRNA for 72 hours prior to RNA isolation. Cells were also treated with 
100 µM Fe2+ for 48 hours or (B) 100 nM α-Toc for 24 hours prior to RNA isolation. Data shown 
as % of untreated control cells, n=3, * indicates P<0.05 and ** indicates P<0.01. 
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4.2.3 Oxidative stress in TRPML1-deficient RPE1 cells decreases mitochondrial 
metabolic function 
To confirm the second part of my hypothesis, that a candidate gene is transcriptionally activated 
and induces changes in mitochondrial morphology and function, I first examined the effects that 
loss of TRPML1 had on mitochondrial metabolism and glycolytic function. As our lab recently 
published data showing that loss of TRPML1 results in the production of ROS that actively damage 
the cell, indicated by mitochondrial fragmentation and loss of mitochondrial membrane potential, 
I was interested in determining if these changes altered the ability of the mitochondria to utilize 
oxygen to produce ATP. To test this hypothesis, I measured mitochondrial metabolism utilizing 
the Seahorse Extracellular Flux Analyzer in cells deficient of TRPML1. Using this assay, I was 
able to obtain a comprehensive analysis of basal cellular oxygen consumption rates, which 
provided information about mitochondrial health and information about the glycolytic function of 
the cell with regards to conversion of pyruvate to lactic acid. While experiments were only 
performed in control, TRPML1, and TRPML1+Fe2+-KD RPE1 cells, future experiments will have 
to be repeated to examine the status of cells with and without GDAP1. Experiments in Figure 24A 
indicated that there were no significant differences in cellular glycolytic function between any 
condition, while Figure 24B and Figure 24C indicates that loss of TRPML1 results in significantly 
lower basal oxygen consumption rates, significantly lower ATP-linked oxygen consumption, and 
significantly lower maximal respiration rates in both TRPML1-deficient RPE1 cells with and 
without Fe2+. To determine if the increased expression of GDAP1 in TRPML1-deficient cells is 
responsible for altering mitochondrial membrane potential, a JC-1 fluorometric assay was 
performed. Figure 25 showed that in TRPML1-deficient RPE1 cells, mitochondria are depolarized 
by 25% of control. GDAP1-deficient RPE1 cells are similar to control potential. Surprisingly, 
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Figure 25 showed that cells deficient for both TRPML1 and GDAP1, mitochondrial depolarization 
is rescued. Suggesting that the second part of my hypothesis is true, that GDAP1 is induced by 
ROS in response to loss of TRPML1, which then induces mitochondrial damage. It will be 
interesting to see if the double knockouts can rescue mitochondrial metabolism and morphology.  
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Figure 24 Oxidative stress in TRPML1-deficient RPE1 cells inhibits mitochondrial metabolic 
function 
(A) Extracellular acidification rates (ECAR) and (B) Oxygen consumption rates (OCR) were 
measured using the XF24 analyzer prior to addition of chemicals to obtain the basal respiration 
rate, and after each addition of oligomycin, CCCP, and antimycin A. (C) ATP-linked OCR rates 
were calculated between control and treatment by averaging the drop in OCR following 
oligomycin. ** indicates P<0.01. 
 
 
 94 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 25 Mitochondrial depolarization in TRPML1-deficient RPE1 cells is dependent on 
upregulation of GDAP1 
Analysis of mitochondrial depolarization in RPE1 cells transfected with control, TRPML1, 
GDAP1, or TRPML1 + GDAP1 siRNA 72 hours prior to experiment. As a positive control, cells 
were treated with 10 µM CCCP for 15 minutes prior to experiment. Data are shown as % of 
control-KD cells, n=3, ** indicates P<0.005.  
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4.3 DISCUSSION  
In an effort to verify the oxidative stress observed in my previous publication, I examined HO-1 
and NQO1 levels in brain samples from MLIV mice, the results from this experiment and the one 
performed in MLIV patient fibroblasts indicate that the RPE1 model of oxidative stress induced 
by loss of TRPML1 are recapitulated in other models. In an attempt to identify the molecular 
mechanisms of MLIV pathogenesis, I analyzed previous microarrays in search of a gene candidate 
that was activated by ROS and altered mitochondrial morphology. The results I obtained from the 
microarray were extremely promising, as GDAP1 fit both descriptions. It is known to function in 
mitochondrial fragmentation and was recently shown to be regulated in response to oxidative stress 
(182,187). Not only did the gene candidate appear on the microarray, but GDAP1’s expression in 
both MLIV patient fibroblasts and TRPML1 RPE1 cells was also elevated.  
Two of the most promising and interesting aspects of this study are the fact that α-
tocopherol reversed the GDAP1 upregulation indicating that GDAP1 is upregulated in response to 
the oxidative stress burden in TRPML1 deficient cells. And the fact that double knockdown of 
GDAP1 and TRPML1 in the same cells reversed the mitochondrial depolarization observed in 
TRPML1-deficient RPE1 cells alone. Both of these results support my hypothesis that TRPML1 
loss induces oxidative stress, which increased the expression of GDAP1, a protein that regulates 
mitochondrial morphology and as seen here mitochondrial membrane potential. Future 
experiments measuring mitochondrial metabolism and examining mitochondrial morphology will 
provide more information about the role GDAP1 plays in mitochondrial morphology with regards 
to TRPML1’s functional status.  
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5.0  CONCLUSION AND FUTURE DIRECTIONS 
Until recently, the centric view of the lysosome was an organelle that participated solely in cellular 
digestion. With the recent discovery of TFEB, the master regulator of lysosomal biogenesis, 
autophagy, and lysosomal function, the role of the lysosome has grown drastically 
(4,17,20,21,114,230,231). While the role of the lysosome in the cell is constantly expanding, 
evidence from our lab suggests that the lysosome functions as a cytoprotective organelle that works 
to sequester cytotoxic material, such as transition metals, thus preventing cellular damage to other 
organelles (23,103,232). The majority of my thesis work over the past five years has focused on 
the involvement of TRPML1 in the cytoprotective function of the lysosome. The results of this 
work are summarized below. 
This work has led to a better understanding of TRPML1s role in lysosomal transition metal 
homeostasis with regards to Fe2+ and has also provided new developments into the molecular 
mechanisms of MLIV pathogenesis. Additionally, these studies provide a novel therapeutic 
approach for alleviating ultra-structural and clinical aspects of MLIV pathogenesis. While the 
functional significance and efficacy of these treatments still need to be evaluated in MLIV animal 
models, it is likely that the use of these treatments could prolong the lifespan of animals and/or 
decrease the rate of MLIV disease progression, as similar studies have shown success in the 
treatment of other LSDs (233). Since a handful of LSDs have increased levels of ROS, this 
therapeutic treatment may extend to several other LSDs. While several questions about the exact 
role of TRPML1 within the lysosome remain unanswered, my work suggests that the role of 
TRPML1 within the cell extends beyond the lysosome. 
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5.1 TRPML1 LOSS RESULTS IN ROS ACCUMULATION 
In Chapter 3, I performed experiments indicating that Fe2+ retention in lysosomes of TRPML1-
deficient cells catalyzes the formation of ROS in lysosomes. Based on the evidence that TRPML1-
deficient cells accumulate lysosomal Fe2+ and the recent discovery that TRPML1 acts as an 
endolysosomal Fe2+ release channel, I hypothesized that in the absence of a functional TRPML1 
channel, Fe2+ retained in the lysosome will have detrimental effects on the cell (58). Since 
lysosomally localized Fe2+ can participate in Fenton chemistry, I first examined the possibility that 
it could catalyze ROS within the lysosome. To test this hypothesis, I utilized a cell culture model 
of MLIV, where TRPML1 levels were modulated in RPE1 cells using a siRNA-based approach. 
Using this system, I determined that the loss of TRPML1 results in the accumulation of ROS, as 
measured by increases in HMOX1 mRNA levels. While my system simulates an “acute” loss of 
TRPML1, as TRPML1 was knocked down for only 72 hours, I wanted to determine if Fe2+ levels 
present in “chronic” models of MLIV potentiate the production of ROS. To test this hypothesis, I 
exposed TRPML1-deficient cells to 100 µM Fe2+ for 24 hours and found that ROS levels were 
even higher, as measured by a larger increase in HMOX1 mRNA levels compared to TRPML1-
KD alone. To support my finding that loss of TRPML1 results in the production of ROS, I 
measured the levels of lipid peroxidation and found more oxidation in TRPML1-deficient cells. 
Surprisingly, all of these changes that occur in TRPML1-deficient cells as a result of ROS 
production can be reversed by the addition of the antioxidant α-tocopherol. This result was very 
exciting and suggests the possibility that therapeutic antioxidant treatment may alleviate some 
symptoms of MLIV pathogenesis.  
In support of these results, I wanted to confirm the possibility that oxidative stress is a key 
factor in MLIV pathogenesis. To test this hypothesis, I examined levels of HMOX1 mRNA in 
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MLIV patient fibroblasts and found it to be elevated, confirming my findings in the TRPML1-
deficient RPE1 model. Additionally, as a collaboration with Susan Slaugenhaupt’s lab at Harvard 
Medical School, I obtained brain samples from 2 and 6 month old MLIV mouse models and 
performed doubly blind analysis to examine the induction of oxidative stress. In MCOLN1 -/-
samples, I observed elevated levels of HO-1 and NQO1, another gene regulated by Nrf2, 
suggesting that oxidative stress indeed plays a role in MLIV pathogenesis. The establishment of 
these finding were very exciting, as they suggest that symptoms associated with MLIV 
pathogenesis in all of these models systems may respond to antioxidant therapeutic treatments.  
As few reliable methods are available to directly measure levels of ROS within the cell, I 
relied on an indirect measurement of ROS by measuring the mRNA levels of a gene known to be 
upregulated in response to oxidative stress and the presence of ROS. Since different types of ROS 
can induce oxidative stress and activate Nrf2 to promote transcription of antioxidant/ 
cytoprotective genes, this measurement likely encompasses several types of ROS (147,149).  
To support the idea that ROS were catalyzed by Fenton chemistry in the lysosome and are 
directly linked to TRPML1’s functional status and the secondary accumulation of lysosomal Fe2+, 
I confirmed that ROS were lysosomally localized using immunofluorescence and carboxy-
H2DCFDA dye. Experiments performed in Chapter 3 confirmed that ROS generation was likely 
localized to the lysosome, as mitochondrial superoxide production was not detected in any 
condition. In several models of oxidative stress, ROS generated within the lysosome leads to 
peroxidation of membrane lipids and ultimately results in destabilization of the membrane and 
eventual lysosomal membrane permeabilization (LMP) (234,235). The resulting LMP then allows 
lysosomal contents to leak out into the cytoplasm, where lysosomal enzymes have the potential to 
activate caspases and the apoptotic cascade to initiate cell death (234).  
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Measurement of both Annexin V binding and Caspase 3 activity indicated no activation of 
apoptotic cell death cascades in TRPML1-deficient RPE1 cells regardless of Fe2+ status. This 
suggests that accumulation of ROS in lysosomes deficient of TRPML1 is not enough to induce 
cell death in the RPE1 model of MLIV. Interestingly, the absence of cell death initiation may be 
cell type specific, as data from our lab previously indicated that TRPML1 deficiency in HeLa cells 
results in the release of Cathepsin B from the lysosome which promotes cytochrome C release 
from the mitochondria and activation of Caspase-3, likely inducing eventual cell death (189). 
While there seems to be cell type specific differences between these cell model systems, how ROS 
impact the integrity of lysosomes upon modulation of TRPML1 and whether antioxidant treatment 
can alleviate MLIV symptoms will ultimately need to be analyzed in MLIV patient cells or the 
MLIV mouse model.  
5.2 MITOCHONDRIAL HEALTH IN MLIV 
In the remainder of Chapter 3 and Chapter 4, I performed experiments indicating that ROS 
produced in TRPML1-deficient cells induced cellular dysfunction outside of the lysosome, 
specifically within the mitochondria. The results in this section suggest that loss of TRPML1 in 
RPE1 cells results in changes in mitochondrial morphology that is directly related to the production 
of ROS.  
Here I showed that TRPML1 loss is associated with mitochondrial fragmentation. The 
relatively short time to development and TRPML1-specificity of this phenotype suggests that this 
phenotype is an active event caused by the loss of TRPML1 and perhaps further aggravated by the 
induced lysosomal deficits and/or Fe2+ accumulation associated with MLIV. The fact that this 
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fragmentation is reversed by ROS reduction with the antioxidant α-tocopherol is new. It suggests 
that ROS generated from TRPML1-deficient cells damages mitochondria. This is a unique 
observation connecting TRPML1 to processes outside of the lysosome.  
In conjunction with this, Chapter 4 supports the idea that TRPML1 loss induces oxidative 
stress, which increased the expression of GDAP1 and decreased the expression of MFN1, both are 
proteins that regulates mitochondrial morphology. Additionally, TRPML1 loss also reduced 
mitochondrial membrane potential. This alone adds a whole new dimension to what I know about 
the molecular mechanisms leading to MLIV pathology. Not only can I reverse this process with 
antioxidants, I now have a protein target, which is down stream of the loss of TRPML1 that I can 
target to alleviate mitochondrial damage. The model in Figure 26 summarizes the results from 
Chapter 3 and Chapter 4. While little is known about the exact function of GDAP1 in 
mitochondrial dynamics, future research will focus on identifying how GDAP1 senses the 
oxidative stress burden and in return alters mitochondrial morphology.  
Since MLIV patient cells have been shown to have defects in autophagy, it is possible that 
fragmented and damaged mitochondria may accumulate in TRPML1-deficient cells since they are 
unable to be recycled via autophagy and lysosomal degradation (49,236). My data indicates that 
the production of ROS in the lysosome are at least partly responsible for the presence of 
fragmented dysfunctional mitochondria, as this phenotype is reversible with the antioxidant α-
tocopherol. This observation that ROS are responsible for causing the associated mitochondrial 
dysfunction seems to be unique to MLIV, as other LSDs, such as the Mucopolysacchridoses, have 
been shown to induce mitochondrial dysfunction as a direct result of autophagic dysfunction (237).  
 While data in Chapter 3, indicates that apoptotic cascades are not initiated in my RPE1 
model, perhaps due to the short time of TRPML1 modulation, mitochondrial dysfunction in MLIV 
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patient fibroblasts has been associated with loss of mitochondrial Ca2+ buffering capacity (23,24). 
As loss of mitochondrial Ca2+ buffering capacity is associated with increased sensitivity to 
apoptosis (238,239). It is possible that in other cell types mitochondrial dysfunction induced by 
TRPML1 deficiency may activate apoptosis, as was previously seen by our lab in HeLa cells (189). 
While the centric view of MLIV pathology is shifting towards microglial and astrocyte activation 
rather than neuronal death, which revealed the lack of cell death, future research identifying the 
impact of oxidative stress and mitochondrial dysfunction in the central nervous system of MLIV 
mice will provide valuable insight into the status of apoptotic cascade initiation.  
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 Figure 26 Model of TRPML1 deficiency in RPE1 cells 
(A) Under normal conditions, Fe2+ enters the lysosome via endocytosis of Fe2+ bound proteins. 
The proteins are degraded and Fe2+ is transported to the cytoplasm via TRPML1 ion channel. In 
the cytoplasm, Fe2+ binds to low affinity chelators. Under these conditions, mitochondria remain 
elongated and are capable of normal metabolism. (B) In MLIV cells, which lack TRPML1, Fe2+ 
that is normally transported to the cytoplasm, accumulates in the lysosome and catalyzes Fenton 
reactions resulting in the production of ROS. ROS oxidize lipids, which can permeabilize the 
lysosomal membrane, allowing ROS to access the cytosol and induce mitochondrial fragmentation 
and loss of ΔΨm. Increased levels of oxidative stress upon loss of TRPML1 induce GDAP1 
dependent mitochondrial fragmentation and result in reduced mitochondrial metabolism. While 
not depicted, several of these perturbations are reversible via the addition of the antioxidant α-
tocopherol.  
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APPENDIX A 
THE COMPARISON OF THE LOSS OF TWO LYSOSOMAL PROTEINS 
ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION TO IDENTIFY A 
MECHANISM REGULATING LYSOSOMAL AND MITOCHONDRIAL HEALTH 
The work discussed in this section is unpublished. 
A.1 OVERVIEW 
Previously I have focused my work on the loss of TRPML1, to investigate this mechanism 
in a broader fashion I have also focused on the loss of ATP13A2. ATP13A2 is a member of the 
P5 subfamily of ATPases involved in lysosomal cation transport and mutations in this gene are 
associated with Parkinson’s disease (197). I hypothesize that loss of a lysosomal protein is 
sufficient to directly cause mitochondrial damage. The alternative hypothesis is that accumulation 
of bad mitochondria occurs as an indirect mechanism induced by inhibition of autophagy. To test 
this aim, I started by confirming that the loss of both TRPML1 and ATP13A2 result in 
mitochondrial dysfunction characterized by loss of mitochondrial membrane potential. 
As multiple neurodegenerative disorders, including other lysosomal storage diseases and 
Parkinson’s disease, show defective lysosomal function, accumulation of transition metals, and 
buildup of unhealthy mitochondria, I am currently trying to identify a broad target that can be used 
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to alleviate these symptoms. Recently, it has been shown that overexpression of TFEB, the 
transcription factor known to regulate lysosomal and autophagic biogenesis as well as secretion, 
can successfully alleviate storage phenotypes by upregulating exocytosis, specifically in Pompe 
disease (114). Whether or not overexpression of TFEB can alleviate the lysosomal linked 
mitochondrial damage in neurodegenerative disorders has not been studied. To test the hypothesis 
that TFEB overexpression can alleviate mitochondrial damage induced by loss of lysosomal 
proteins, I will overexpress TFEB in cells that are deficient for multiple lysosomal proteins 
associated with neurodegenerative disorders and examine if mitochondrial dysfunction and 
damage is rescued by TFEB overexpression. For these experiments I will examine mitochondrial 
membrane potential. If TFEB overexpression can alleviate mitochondrial damage, I expect to see 
membrane potential return to control levels, suggesting that overexpression of TFEB is a 
successful treatment for mitochondrial damage associated with neurodegenerative diseases. 
However, if TFEB overexpression is not sufficient to rescue these phenotypes, I will pursue other 
avenues such as the activation of TRPML1, which should also prevent mitochondrial damage by 
sequestering transition metals like iron in the lysosome.  
These studies will not only provide future direction for treatment of MLIV, in addition to 
my previously suggested treatments with antioxidants, but the results obtained from this study will 
allow us to more broadly treat neurodegenerative disorders where both the lysosome and 
mitochondria are dysfunctional.  
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A.2 PRELIMINARY DATA 
 
 
 
 
 
 
 
 
 
 
Figure 27 Oxidative stress is induced in TRPML1-deficient RPE1 cells, but not ATP13A2-
deficient RPE1 cells 
HMOX1 mRNA expression assessed by qPCR in control, TRPML1, and ATP13A2-KD cells. Data 
were normalized to values detected in untreated control-KD cells, which were taken as 100%. Data 
are means ± S.E.M.n=3, ** P<0.01.  
 
 
 
 
 
 
 107 
  
 
 
 
 
 
 
 
Figure 28 Loss of TRPML1 and ATP13A2 in RPE1 cells induces mitochondrial 
depolarization 
Analysis of mitochondrial depolarization in RPE1 cells transfected with control, TRPML1, 
ATP13A2 siRNA 72 hours prior to experiment. As a positive control, cells were treated with 10 
µM CCCP for 15 minutes prior to experiment. Data are shown as % of control-KD cells, n=3, ** 
indicates P<0.01. 
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Figure 29 Mitochondrial depolarization is rescued by TFEB overexpression in ATP13A2-
deficient HEK cells 
Analysis of mitochondrial depolarization in HEK cells transfected with MOCK or TFEB plasmid, 
followed by transfection with control, TRPML1, ATP13A2 siRNA 72 hours prior to experiment. 
As a positive control, cells were treated with 10 µM CCCP for 15 minutes prior to experiment. 
Data are shown as % of control-KD cells, n=3. 
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APPENDIX B 
OXIDATIVE STRESS IN TRPML1-DEFICIENT RPE1 CELLS ACTIVATES 
INFLAMMATORY PATHWAY TRANSCRIPTIONAL REGULATION 
 
 
 
 
 
 
 
 
 
 
Figure 30 TRPML1 deficiency in RPE1 cells induces NF- κB p50 nuclear translocation in an 
ROS dependent manner 
(A) Western blot analysis of RPE1 cells transfected with control or TRPML1-siRNA 72 hours 
prior to analysis. As a positive control, cells were treated with 40 ug/mL of TNF-α for 8 hours. As 
a means of reducing oxidative stress, cells were pretreated with 100 nM α-Toc fir 24 hours prior 
to analysis. (B) Quantitative analysis of NF-κB p50 nuclear translocation normalized to actin and 
shown as % of control. n=3, **indicates P<0.01. 
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APPENDIX C 
CHARATERIZING THE CELLULAR RESPONSE TO DEFECTS IN ENDOCYTIC 
TRAFFICKING 
The work discussed in this section is unpublished data. 
 
Endocytosis is an essential process in all cells. It is used to absorb nutrients, regulate protein 
surface expression, and functions in membrane remodeling and cell signaling. It is unclear how 
this process is regulated and if cells are able to gauge defects in this pathway. I propose that cells 
have specific regulatory networks to monitor and respond to trafficking defects along the endocytic 
pathway. To test this hypothesis, I have established a system in which I can modulate different 
steps of the endocytic pathway to produce trafficking defects. To modulate aspects of endocytosis, 
siRNA was used to target the following proteins, RAB5A, RAB7A, TRPML1 and 3, PPT1 and 
TPC. Western blotting and quantitative real-time PCR confirmed significant down regulation of 
both protein and mRNA levels. To confirm the presence of trafficking defects, I plan to perform 
fluorescent trafficking assays using the fluid phase endocytic marker dextran and quantitative 
radioactive assays. Once trafficking defects are identified, I plan to measure the genomic response 
using microarray analysis to assemble gene expression profiles. Gene expression profiles will be 
compared between all endocytic trafficking defects to determine if similar genes are altered. 
Furthermore, to identify common regulatory elements responsible for the genomic response, I will 
compare transcription factors associated with up and down regulated genes. The results of this 
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study will provide insight into how the endocytic pathway is regulated when the pathway is 
disrupted.  
C.1 INTRODUCTION 
Regulatory gene networks are responsible for monitoring organelle biogenesis and cellular stress 
responses within the cell (166). Endocytosis is a highly complex process responsible for nutrient 
absorption, membrane remodeling, and cell signaling (240). How this pathway is regulated is not 
well understood. Recently, a regulatory gene network (CLEAR network) associated with the latter 
portion of the endocytic pathway was identified. This network is responsible for regulating 
lysosomal biogenesis through activation of the master transcription factor EB (TFEB) (166). Not 
all genes coding for endocytic proteins contain TFEB binding sites, which suggests that TFEB is 
not the only transcription factor regulating endocytosis. Little is known about what signals feed 
into this pathway and what is responsible for the continual movement of cargo through the 
endocytic pathway. I propose that acute knockdown of endocytic proteins followed by gene 
expression assays will identify specific regulatory networks that gauge the status of endocytic 
compartments and respond to trafficking defects along the endocytic pathway.  
When the endocytic pathway is not functioning properly to deliver and digest cargo, it can 
result in the accumulation of storage bodies in the cytoplasm, which are a characteristic of storage 
diseases. Interestingly, storage diseases are commonly associated with neurodegeneration due to 
cell death. Multiple storage diseases, including Mucolipidosis type IV, Infantile Neuronal 
Lipofuscinosis, and Charcot-Marie-Tooth disease type 2B, are associated with protein malfunction 
in the endocytic pathway, more specifically with defects in TRPML1, PPT1, and RAB7A 
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respectively (28,241,242). I propose that genomic responses to problems in the endocytic pathway 
may contribute to the pathological manifestations of storage diseases. I will test this suggestion by 
acutely knocking down proteins that are implicated in storage diseases and endocytic function. 
These experiments will lend insight into how cells respond at the genomic level to defects at 
different points along the endocytic pathway. This study will provide a more accurate depiction of 
trafficking defects generated as a direct result of disrupting the function of important endocytic 
proteins. The results of this study will provide valuable information about the genomic response 
associated with different lysosomal storage disorders and diseases associated with the disruption 
of the endocytic pathway. This study will also provide analysis of the localization and activity of 
transcription factors directly responsible for the cellular response to trafficking defects.  
C.1.1 Endocytosis 
Endocytosis is an essential process in all cells. It is used to absorb nutrients, regulate protein 
surface expression, and functions in membrane remodeling, cell signaling, and intracellular 
transport (240). In order for cells to perform these tasks, they need to maintain trafficking 
throughout the entire pathway (240). The endocytic pathway is composed of multiple 
compartments, each with a unique function. This process is highly complex and relies on multiple 
proteins to coordinate specific events, such as vesicle movement, maturation, and fusion/fission 
events. During internalization, cargo is initially delivered to the EE, where it is either sorted for 
degradation or recycled back to the plasma membrane (240). The early endosome contains the 
small GTPase RAB5A, which mediates fusion between clathrin coated vesicles and early 
endosomes (Figure 31) (243). As cargo transits through the pathway, the EE fuses with the LE, 
where cargo begins to undergo degradation (240). As trafficking continues, the LE fuses with the 
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lysosome, where degradation is completed prior to absorption of nutrients and materials (240). 
Fusion of the EE and LE as well as fusion of the LE and lysosome is regulated by the small GTPase 
RAB7A (Figure 31) (243). It is unclear how this trafficking process is regulated, but previous 
studies have identified key proteins and phosphoinositides that when mutated or knocked down 
result in the formation of storage bodies (190,244-247). The presence of storage bodies, indicating 
a delay or block in endocytosis, is a hallmark of LSD (248). Utilizing the specificity of RAB 
proteins, I can establish defects that specifically disrupt the function of distinct compartments 
along the endocytic pathway.  
To determine how endocytosis is regulated, specific aspects of trafficking will be disrupted 
by inhibiting protein synthesis, decreasing levels of phosphoinositides, or treating cells with 
pharmacological compounds. The molecules displayed in Figure 31 were selected for modulation 
because they play an important role in endocytic events and/or are implicated in storage diseases. 
The first candidate is TRPML1, an inwardly rectifying cation channel, activated by PI(3,5)P2 (79). 
TRPML1 localizes to the lysosome and is thought to regulate fusion/fission between the late 
endosome and lysosome (86). Mutations in the gene MCOLN1, encoding for TRPML1, are 
associated with Mucolipidosis IV and result in neurodegeneration characterized by developmental 
delays, retinal degeneration, and motor and cognitive deficiencies (28). The second candidate is 
TRPML3, a pH regulated Ca2+ channel localized to the endocytic pathway (245). Overexpression 
studies of MCOLN3, the gene encoding TRPML3, suggests that it plays an important role in 
endosomal function because it results in enlargement and clustering of endosomes (200,245). 
Alternatively, impairment of TRPML3 results in defective membrane trafficking and endosomal 
acidification (245). The third candidate is TPC1, a Ca2+ permeable channel activated by NAADP 
localized to endo/lysosomal compartments (249). The release of Ca2+ from the lysosome may also 
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facilitate fusion/fission events. The fourth candidate is PI(3,5)P2, a phosphoinositide localized to 
the LE and lysosome (246). Recent publications have identified it as the main activator of 
TRPML1 (79). The loss of PI(3,5)P2 results in enlarged endo/lysosomes (79). PI(3,5)P2 is 
produced from PI(3)P via the kinase PIKfyve/PIP5K3 (246). To decrease levels of PI(3,5)P2, the 
kinase will be targeted using siRNA. The fifth candidate is RAB5A, a small GTPase localized to 
the early endosome. RAB5A is responsible for mediating fusion between internalized vesicles and 
early endosomes (244). The sixth candidate is RAB7A, another small GTPase responsible for 
facilitating vesicle fusion/fission between the EE and LE and the LE and the lysosome (247). 
RAB7A has also been shown to be necessary for lysosomal degradation of an endocytic receptor 
complex, EGF-EGFR (247). Mutations in RAB7A are associated with Charcot-Marie-Tooth Type 
2B Neuropathy, which is characterized by muscle weakness and wasting along with sensory loss 
(241). The seventh candidate is PPT1, a lysosomal enzyme thought to be involved in the 
degradation of lipid-modified proteins (228). Like TRPML1, mutations in PPT1 are associated 
with a lysosomal storage disorder, known as Infantile Neuronal ceroid lipofuscinosis (242).  
Aside from modulating endocytosis by RNA silencing, multiple pharmacological 
compounds are commercially available to target specific aspects of the endocytic pathway. 
Calcium is an important molecule in many cellular processes and recent publications have 
indicated a role for Ca2+ release in endo/lysosomal fusion (250). As a means of inhibiting this 
event, a Ca2+ chelator, BAPTA-AM is used to cause trafficking defects by inhibiting vesicle 
fusion/fission (190). Another aspect of endocytosis necessary for trafficking is the proper 
acidification of endocytic compartments. Compartmental acidification is maintained by vacuolar 
H+-ATPase pumps, inhibition of this pump was shown to slow delivery to late 
endosomes/lysosomes (240). Bafilomycin A1, a compound that blocks lysosomal acidification, 
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can inhibit the H+-ATPase pump (240). The lysosome is the final destination for all cargo that 
enters the endocytic pathway to be degraded. It contains multiple acid hydrolase enzymes used to 
digest nutrients and breakdown cellular debris and waste (240). Leupeptin, a serine/cysteine 
protease inhibitor, is used to inhibit the degradative properties of lysosomal enzymes therefore 
preventing degradation of protein substrates (251). Specifically modulating different aspects of the 
endocytic pathway using siRNA or pharmacological compounds will allow us to determine if a 
single regulatory gene network is responsible for gauging the status of the entire endocytic 
pathway. Anticipated results of modulating proteins along the endocytic pathway are indicated in 
Table 4.  
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Figure 31 Localization of proteins and phosphoinositides associated with endocytic traffic 
(A) The distribution of PI(4,5)P2, PI(3)P2, and PI(3,5)P2 associated with the plasma membrane and 
membranes of the early endosome and late endosome/lysosome are represented by blue, orange, 
and yellow outlines, respectively. Green circles represent cargo/probes for fluid phase endocytosis.  
 
Table 4 Anticipated trafficking defects produced as a result of modulating endocytic proteins 
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C.1.2 Regulatory Gene Networks 
Regulatory gene networks have recently been implicated for monitoring several biological 
processes including stress responses. One example of a regulatory gene network is the activation 
of the unfolded protein response within the endoplasmic reticulum that activates the transcription 
factor Atf6 (252). Regulatory gene networks also play a role in organelle biogenesis and 
maturation processes. As previously mentioned, the first regulatory gene network associated with 
the endocytic pathway was recently discovered. This network, known as the CLEAR (Coordinated 
Lysosomal Expression and Regulation) network, regulates biogenesis and function of the 
lysosome (19). The CLEAR network is activated upon conditions of starvation or lysosomal 
disruptions. Both conditions activate the master transcription factor, TFEB, which enters the 
nucleus and binds to a consensus sequence within the promoter known as the CLEAR sequence 
(19). This results in the transcription of lysosomal genes necessary for lysosomal biogenesis (19). 
The function and activity of the endocytic pathway is well established, but little is known about 
how this pathway utilizes signaling to regulate trafficking. The identification of the CLEAR 
network suggests that regulatory gene networks monitor the endocytic pathway. 
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C.2 RESULTS 
C.2.1 Establish and characterize distinct trafficking defects by modulating endocytic 
proteins and phosphoinositides 
To establish a toolbox of endocytic disruptions that will be used to examine the cellular response 
to trafficking defects I have knocked down several candidate proteins. They include TRPML1, 
TPC1, PPT1, RAB7A, RAB5A, FIG4, VAC14, and PIP5K3. Figure 32A shows the quantification 
of mRNA levels after siRNA KD using q-PCR, while Figure 32B shows protein levels using 
Western blot analysis. The results from these figures indicate that siRNA down regulation results 
in decreased mRNA and protein levels. These initial results also indicate that siRNA is an effective 
method for targeting specific endocytic proteins.  
As a means of monitoring endocytosis, fluorescent probes conjugated to dextran are 
internalized through fluid phase endocytosis. Upon internalization, the assay is stopped at specific 
timepoints by fixing the cells. Once fixed, the cells are assayed by immunofluorescent staining 
with antibodies specific to an endocytic compartment. The antibodies that are typically used 
include, EEA1 (BD-Transduction Laboratories) to stain the EE, M6PR (AbCam) to stain the LE, 
and LAMP-1 (Santa Cruz Biotechnology) to stain lysosomes. This assay provides “snapshots” of 
the endocytic pathway by comparing the localization of fluorescent dextran with specific endocytic 
markers. Previous publications studying lysosomal storage disorders examine the uptake of 
fluorescent dextran with long load and chase times (53). Using this procedure TRPML1 KD, 
PIP5K3 KD and control KD cells were loaded with Texas red dextran for 3 hour, followed by 
chase of either 0 or 6 hours. The results from this assay are shown in Figure 33A and quantified in 
Figure 33B. This procedure revealed similar co-localization between dextran and the lysosomal 
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marker LAMP-1 after a 6 hour chase for all treatments. Although this data alone suggests that 
there may not be a trafficking delay because dextran is still delivered to the lysosome, the 
resolution of this protocol may not be good enough to see a delay. If this is the case, this procedure 
is not optimal for my study because I am interested in localizing trafficking defects to both early 
and late compartments along the endocytic pathway. To confirm the presence or absence of minute 
trafficking delays, I need an assay that is more sensitive to detect delays at earlier time points in 
the endocytic pathway. To do this, I have developed a revised protocol that utilizes short load (5 
minute) and chase (0, 20, 60 minute) times to get a better representation of each endocytic 
compartment, rather than just the lysosome. Figure 34 shows the revised protocol is sensitive 
enough to resolve trafficking between specific endocytic compartments including the EE and 
lysosome. Using this assay, I will be able to monitor trafficking defects throughout the entire 
endocytic pathway and specifically pinpoint the location of any trafficking defects. Future work 
will involve performing individual trafficking assays in combination with different siRNA.  
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 Figure 32 siRNA-mediated down regulation of endocytic proteins 
(A) HeLa cells were transfected with respective siRNA 48 hours prior to isolation of RNA. Total 
RNA was isolated and cDNA was synthesized and probed using primers spanning exons. 
Experimental samples were normalized to housekeeping gene, β-Actin. **P<0.01. (B) HeLa cells 
were transfected with respective siRNA and lysates were collected 48 hours after transfection and 
subjected to Western blot analysis using the respective antibodies. Protein levels were normalized 
to β-Actin. Note TRPML1 and PPT1 in RPE1 cells were also analyzed using this method. These 
results are shown in Figure 22. 
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 Figure 33 Texas red dextran delivery to lysosomes after long load and long chase times does 
not provide enough resolution to distinguish trafficking delays in TRPML1 and PIP5K3 
deficient cells 
(A) HeLa cells were treated with Control, TRPML1, or PIP5K3 siRNA for 48 hours then loaded 
for 3 hours with Texas Red (TR) dextran. Following a 3 hour load, cells were washed with regular 
media and fixed (0 hour chase) or chased for an additional 6 hours. Cells were then fixed and 
processed for immunofluorescence. Delivery of TR dextran to lysosomes was measured by 
quantifying the percent overlap between TR dextran and the lysosomal marker, LAMP-1. (B) 
Graphical representation of the quantifications are shown and are expressed as the percent overlap 
± SEM for cells under each condition. n=5.  
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Figure 34 Trafficking assays with Alexa Fluor 488 dextran using short load and chase times 
can be used to pinpoint the time it takes for cargo to be delivered to the early endosome and 
lysosome in control cells 
HeLa cells transfected with control siRNA were loaded for 5 minutes with Alexa Fluor 488 (A488) 
dextran. Following a 5 minute load, cells were washed with regular media and fixed (0 minute 
chase) or chased for either an additional 20 minutes or 1 hour. Cells were then fixed and processed 
for immunofluorescence. Delivery of A488 dextran to early endosomes was measured by 
quantifying the percent overlap between A488 dextran and the early endosomal marker, EEA1. 
While delivery to the lysosome was measured using the lysosomal marker, LAMP-1.  
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C.3 DISCUSSION AND FUTURE DIRECTIONS 
The goal of this project is to determine if the cell is able to sense a disruption in endocytic 
trafficking. More specifically, with the results of this project, I will be able to establish a cellular 
response model for endocytic trafficking defects and determine if the cell responds in a general 
manner to all endocytic assaults or in a manner that is specific to the location of the defect along 
the endocytic pathway. Upon analysis of the transcription factors identified using the microarray 
analysis I will determine which regulatory networks are acting in response to defects and how 
these networks are activated.  
C.3.1 Endocytic trafficking assays are sensitive enough to detect defects in endocytosis 
My results confirm that siRNA modulation can effectively down regulate mRNA and protein 
levels of several endocytic proteins. Using this technique to modulate protein expression, I was 
able to examine endocytic trafficking by monitoring fluid phase endocytosis of the fluorescent 
probe, dextran. Performing this assay with long load and long chases, indicates that there may be 
trafficking defects present upon modulation of TRPML1 and PIP5K3 KD, but these assays are not 
sensitive enough to resolve the localization of the trafficking defect. As a way to better resolve the 
specific location of each trafficking defect along the endocytic pathway, I developed a protocol 
that utilized short load and short chase times in combination with EE and LE markers to determine 
the rate at which cargo travels through each compartment. My assays performed in control cells 
indicate that the sensitivity of this protocol can be used to examine modulations to the endocytic 
pathway and help to specifically localize the trafficking defect. Future work in our lab will focus 
on this.  
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C.3.2 Acute TRPML1 modulation does not result in changes in gene expression in TFEB 
regulated genes 
Our lab has initiated preliminary analysis of the cellular response to modulations of key endocytic 
proteins. Microarray analysis has been completed for 48 hour KD of TRPML1 in comparison to 
control cells. TRPML1 is a lysosomal protein and therefore the KD may cause lysosomal 
disruption triggering the activation of TFEB and the up or down regulation of CLEAR network 
associated genes. The microarray data obtained indicates that the expression of several genes 
changed upon knocking down TRPML1. Interestingly, none of the genes that were up or down 
regulated are associated with the CLEAR network. This indicates that either 48 hour KD of 
TRPML1 does not cause sufficient lysosomal disruption to activate TFEB or that another novel 
regulatory gene network may be activated in response to TRPML1 KD. Analysis of the 
transcription factors associated with the genes that are up and down regulated in TRPML1 
deficient cells revealed several possible transcription factors that may be responsible for the 
cellular response. The transcription factor that was most frequently associated with genes that had 
differential expression was NF-κB. To determine if NF-κB is the transcription factor responsible 
for the cellular response to TRPML1 KD, I need to perform microarray analysis on other endocytic 
disruptions to see if NF-κB regulated genes are also up or down regulated upon KD. Future work 
will involve performing microarray analysis with other siRNA modulations of the endocytic 
pathway. To answer whether individual endocytic compartments are regulated by the same 
transcription factor or if each compartment utilizes a unique and specific transcription factor for 
the cellular response, I can compare the data from several endocytic disruptions. Additionally, I 
can use this data to differentiate between responses that are due to knocking down a specific protein 
compared to responses that are due to general disruptions of endocytosis. 
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